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ABSTRACT
Yan, Ran. M.S., Department of Biological Sciences, Wright State University, 2013.
Regulation of the stability and cellular localization of the Coxsackievirus and adenovirus
receptor (CAR).

In polarized epithelia, the seven exon isoform of the Coxsackievirus and adenovirus
receptor (CAREx7) is a basolateral cell-cell adhesion protein that is inaccessible for viral
infection. In contrast, the eight-exon CAR isoform (CAREx8) localizes at the apical
surface and mediates adenovirus (AdV) infection. A PDZ-domain containing protein,
MAGI-1, interacts with both isoforms of CAR. I hypothesized that each CAR isoform
interacts with specific MAGI-1 PDZ domain(s). Co-immunoprecipitation, FRET and
binding assays showed that CAREx7 and CAREx8 both interact with MAGI-1-PDZ3 with
high affinity. CAREx8 also interacts with MAGI-1-PDZ1. Whereas the CAREx7-PDZ3
interaction regulates MAGI-1 junction localization, PDZ3 suppresses CAREx8 cell surface
levels and AdV infection. Surprisingly, PDZ1 can rescue CAREx8 from MAGI-1mediated degradation. I also hypothesized that MAGI-1 directs CAREx8 to the ERassociated degradation (ERAD) pathway. Inhibitor experiments demonstrated that
ERAD-UPS is associated with MAGI-1-mediated CAREx8 degradation. These novel
findings provide insight into the stability and cellular regulation of CAR.
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Chapter 1. Introduction

Understanding the cellular function and regulation of the abundance and
localization of viral receptors can provide important information that demonstrates the
mechanism of viral infection and provide potential therapeutic targets. Wild type
adenovirus (AdV) and coxsackievirus are significant civilian and military threats for
acute respiratory disease and cardiomyopathy, and new, highly pathogenic variants
emerge yearly. Adenovirus has further clinical significance as the most common
vector system used in gene therapy clinical trials worldwide. These two distinct
groups of viruses share a common receptor named the coxsackievirus and adenovirus
receptor (CAR). By studying the cellular regulation of CAR, which is the primary
receptor of most adenoviruses, we can either eliminate the receptor in order to reduce
viral infection or transiently increase the receptor availability in order to increase the
gene therapy efficiency. One of the approaches to understanding the cellular
regulation of CAR is to determine what regulates its protein level. This may include
both protein interactions and post-translational modification of CAR, such as
glycosylation, phosphorylation, ubiquitinylation, etc. Identifying the protein binding
partners and protein modification of CAR can reveal information on the degradation,
trafficking and cell-signal pathways that CAR is involved in. This thesis has focused
on the regulation of isoform-specific protein abundance and localization in order to
determine potential therapeutic targets for the prevention of adenovirus infection and
may also potentially provide new approaches to increase the adenovirus-mediated
gene therapy efficiency.
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1.1 Coxsackievirus and adenovirus receptor (CAR)
1.1.1. CAR gene and protein
CAR was first isolated and identified as the primary receptor for two distinct
groups of viruses, Coxsackie B viruses and most adenoviruses (AdV) (1). CAR is
encoded by the CXADR gene, localized to chromosome 21q11.2 in humans. Full
length open reading frame (ORF) mRNA of CAR encodes 365 amino acids (aa),
including a 19 aa leader sequence, a 216 aa extracellular domain, a 23 aa
transmembrane domain and a cytoplasmic domain that varies depending on the
isoform (6) (Fig.1.1) (18). The extracellular domain of CAR contains two Ig-like
domains, D1 and D2. Two CAR molecules from neighboring cells can adhere through
homodimerization of distal Ig-like domain (D1 domain) of the extracellular domain.
AdV fiber knob, which is the fiber knob domain of the AdV fiber, shares the same
interacting surface on the D1 domain where CAR forms D1:D1 homodimers.
Although both the AdV fiber knob and D1 domain from the other CAR molecule bind
to the D1 domain exclusively, deletion of the D2 domain leads to a diffused
localization of CAR in the cell, in contrast to the limited junction localization of
parental CAR. Deletion of the D2 domain of CAR significantly attenuates CARmediated viral binding and infection (16). Each of the Ig domains contains an Nglycosylation site, N106 and N201. Mutation of each N-glycosylation site leads to a 3kD
shift on SDS-PAGE. Although the loss of glycosylation of CAR neither alters the cell
surface expression level nor the cell junction localization, the glycosylation of CAR
still plays a role in CAR-mediated cell adhesion and is required for cooperative
binding of AdV (13). The signal 318YNQV321 in the cytoplasmic domain of CAR is a
tyrosine-based basolateral sorting signal that interacts with clathrin adaptors AP-1A
and AP-1B (9) (2).
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Fig. 1.1 Alternative Coxsackievirus and adenovirus receptor (CAR)
spliceforms and spliceform specific protein sequence.
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The cytoplasmic domain of the major CAR isoform ends with the aa sequence –
GSIV, which is a PSD95/Dlg/ZO-1 (PDZ) binding domain motif (Fig 1.1). This motif
mediates interactions between CAR and PDZ domains found in some PDZ-domain
containing proteins. The cytoplasmic domain of CAR interacts with scaffolding
proteins which are intracellular members of the tight junction, adherent junction, and
actin cytoskeleton (5-7).

1.1.2. Coxsackievirus and Adenovirus Receptor isoforms
Among the several alternatively spliced transcripts of CAR, two transcripts
encode transmembrane splice forms: one that terminates after the seventh exon
(CAREx7) and one that splices from a cryptic splice donor site within the seventh exon
and terminates after the eighth exon (CAREx8). These two isoforms only differ in the
last 26 amino acids (CAREx7) or 13 amino acids (CAREx8) at the C-terminus of the
cytoplasmic domain. Although the two isoforms have distinct C-terminal tails, the last
four amino acids of each isoform comprise type I PDZ binding domains of distinct
sequence (GSIV – CAREx7; ITVV – CAREx8) (14) (Fig 1.1). Interestingly, the two
isoforms have different abundance and cellular localization. The seven-exon isoform
is the most abundant isoform and largely localizes to the cell-cell junctions where it
serves as an adhesion protein that maintains the cell-cell junction. In non-polarized
cell lines, overexpressed CAREx8 localizes to cell-cell junctions as well. In primary
well-differentiated human airway epithelia (HAE), endogenous CAREx7 localizes to
the tight junction and adhesion junction. However, endogenous CAREx8 in HAE
localizes to the sub-apical region of the cell and apical surface above the tight
junction marker ZO-1. Overexpressed CAREx7 in HAE still localizes to the basolateral
membrane, while overexpressed CAREx8 is largely diffuse in the cytoplasm (Fig 1.2).
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Ex7

Fig. 1.2 CAR

Ex8

and CAR

localize and behave distinctly in well-differentiated

primary human airway epithelia (HAE). A) CAR

Ex7

(green) overlaps (yellow) and

is basolateral to the tight junction protein ZO-1 (red). B) CAR

Ex8

(green) localizes

to an apical compartment and is distinct from ZO-1 (red). The arrow indicates
Ex8

CAR

-specific staining above the ZO-1 delineated tight junction. C)

Background staining with pre-immune rabbit serum (green) and ZO-1 (red). Overexpression results in D) CAR
and E) CAR

Ex8

Ex7

localization primarily at the basolateral junctions

localization diffusely and at the apical surface of HAE. F)

Augmenting CAR

Ex8

expression significantly increases apical adenovirus,

encoding β-Galactosidase (Adβ-Gal), transduction over GFP or CAREx7
expressing epithelia *p<0.01. Dotted line represents support membrane; AP,
Apical surface; BL, Basolateral surface. Confocal microscopy (60x oil
immersion).
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Consistent with the apical localization, CAREx8 transduced airway epithelia can
mediate a two fold increase in apical viral transduction compared to CAREx7
transduced cell (Fig 1.2) (14).

1.1.3. Coxsackievirus and adenovirus receptor cellular function
CAREx7 localizes to the basal surface of polarized epithelial cells. One of the
natural functions of CAREx7 is to stabilize the cell-cell adhesion complex. CAREx7
colocalizes with ZO-1, which is a tight junction marker (7). Cell junction components
MUPP-1 (8) and β-actin (24) are binding partners of CAR as well. In polarized
epithelia, tight junction can keep the airway separated from the sterile inside
environment. When the CAR-CAR interaction is disturbed by viral fiber-knob
protein, the cell junction will partially break. This provides a transient opening for
AdV to breach the tight junction and interact with the high levels of CAREx7 on the
basolateral side resulting in an increased chance of viral infection. Disruption of
CAR-CAR interactions by adenovirus, adenovirus fiber protein, or antibody against
CAR, leads to a disruption of the tight junctions and increased transepithelial
permeability (40).

1.2. PDZ domain interactions with CAR PDZ-binding domains
1.2.1. CAR PDZ-binding domain
Both isoforms of CAR contain PDZ binding domains which are motifs
encoded by the last four amino acids of its cytoplasmic tail (-GSIV for CAREx7 and –
ITVV for CAREx8). PDZ (PSD95/Dlg/ZO-1) domains are 80-90 amino acid proteinprotein interaction modules or domains (35). PDZ domain-containing proteins belong
to a large class of biologically important molecules that are considered “scaffolding
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proteins” that bring multiple proteins into a single complex and that often are
involved in the protein sorting pathway (25). A PDZ domain interacts with a PDZbinding motif. A PDZ-binding domain is a four amino acid sequence generally found
at the extreme C-terminus of proteins. There are currently three distinct PDZ binding
domain consensus sequences. Both CAREx7 and CAREx8 have a type I PDZ domain
binding sequence at their extreme C-terminus (-X-(S/T)-X-Φ, where X = any amino
acid and Φ = any hydrophobic amino acid). This suggests that CAREx7 and CAREx8
may be involved in protein complexes by binding PDZ domain-containing proteins
and that they may bind the same or different PDZ domains depending on the degree
of specificity. Previous studies show that a series of PDZ domain-containing proteins,
such as MAGI-1, PICK 1, PSD-95, MUPP-1, LNX1, LNX2, and ZO-1, can interact
with CAREx7 (8, 15, 16, 33, 38). Some of these also interact with CAREx8 (MAGI-1,
PSD-95, LNX1 and LNX2) (33, 38).

1.2.2. Multiple PDZ domain-containing protein MAGI-1
The MAGUK (Membrane-associated guanylate kinase) family is a group of
proteins that contain one or several PDZ domains that allow multiple interactions and
formation of protein complexes. Membrane-associated guanlyate kinase with inverted
domain structure 1 (MAGI-1) is an important protein involved in epithelial junction
composition and stability (28, 37, 41), tumor suppression (4, 27) and viral infection
(19).
MAGI-1 is a member of MAGUK family and contains an inactive guanylate
kinase domain, two WW domains, and up to six PDZ domains (PDZ0-5). It has three
major alternatively spliced isoforms (MAGI-1a, b and c). MAGI-1 co-localizes with
ZO-1 at the tight junctions of cultured epithelia and is considered as a tight junction
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protein (26, 31). Laura et al. (31) showed that the junction localization is associated
with the PDZ domains, not the WW, GK, or carboxy terminus domains. β-catenin is
a MAGI-1 interacting partner as well, and selectively binds to the fifth PDZ domain
of MAGI-1. Interestingly, the fifth PDZ domain together with C-terminus region of
MAGI-1 localize to the nucleus, indicating that the fifth PDZ domain is not sufficient
for MAGI-1 junction localization (31). One of the β-catenin binding partners is Ecadherin, a transmembrane protein and a homodimeric junctional adhesion protein.
Co-immunoprecipitation of MAGI-1, β-catenin and E-cadherin was shown (10).
Besides being an intracellular protein involved in cell junctions, MAGI-1 can bind to
various viral oncogenes as well (19, 39), indicating its role in oncogenesis. The
primary oncogenic protein of type 9 human adenovirus (Ad9), a tumorigenic virus, is
the E4-region encoded open-reading frame 1 (E4-ORF1). E4-ORF1 can associate
with and sequester MAGI-1 in the cytoplasm (19). High risk human papillomavirus
(HPV) oncoprotein E6 binds to MAGI-1 PDZ1 domain and is associated with MAGI1 degradation (19). Human T-cell leukemia virus type 1 (HTLV-1) Tax protein
interacts with MAGI-1. In 293T cells, this interaction can mislocalize MAGI-1 from
detergent-soluble to detergent-insoluble cellular fractions (32). Influenza A virus NS1
protein can also disrupt MAGI-1junction localization by sequestering MAGI-1 away
from plasma membrane. This disruption activates an IFN-β induction signaling (30).
All of these data indicate a significant role for MAGI-1 in tight junction formation
and viral oncogenesis.

1.2.3. MAGI-1 interacts with both isoforms of CAR
Previous data have shown that MAGI-1b (Membrane-associated guanylate kinase
inverted-1 isoform b) interacts with both isoforms of CAR in a PDZ-dependent
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manner (14). The CAREx7 interaction with MAGI-1b leads to co-localization of both
MAGI-1b and CAREx7 at cell junctions. On the other hand, there was no colocalization of MAGI-1b and CAREx8 in the cells. Rather, Western blot analysis of
protein lysates from cells co-transfected with CAREx8 and MAGI-1b showed a
dramatic decrease of CAREx8 protein expression level relative to cells that were
transfected only with CAREx8 balanced with empty plasmid (Fig 1.3). This suggests
that MAGI-1b contributes to the instability or loss of CAREx8. Decreased CAREx8 then
leads to decreased adenovirus infection due to decreased receptor levels (14).
Previous studies also confirm the role of the PDZ-binding domains of both isoforms
of CAR in CAR-MAGI-1 binding. Deletion of the last four amino acid of CAREx7
(CAREx7 ΔGSIV) results in the loss of the junction co-localization between CAREx7 ΔGSIV
and MAGI-1 (15). Additionally, deletion of the last four amino acid of CAREx8
(CAREx8 ΔITVV) results in the co-expression of junction localized CAREx8 ΔITVV and
cytoplasmically diffuse MAGI-1 (14). By switching the last four amino acid of the
two isoforms of CAR and co-expressing the reconstructed CAREx7/8 and CAREx8/7
together with MAGI-1, immunocytochemistry data show that not only the last four
amino acid of each isoforms but also the upstream isoform specific amino acid are
required for the CAR-MAGI-1 isoform specific binding and isoform specific
degradation (14).

1.3. Endoplasmic-reticulum associated degradation (ERAD)
The mechanism behind the MAGI-1 mediated CAREx8 degradation can
potentially provide information on ways to modulate the susceptibility of cells to viral
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Fig. 1.3 Cellular localization of CAR
expression of hCAR
Ex8

hCAR

Ex8

Ex7

Ex7

and CAR

with MAGI-1. Co-

and MAGI-1b-GFP results in the loss of

. In contrast to the co-localization of hCAR

Ex7

(A, red) and

MAGI-1b-GFP (B, green) as shown in panel C (yellow), co-expression
Ex8

of hCAR

(D, G, red) and MAGI-1b-GFP (E, H, green) results in
Ex8

decreased levels of hCAR

(F) unless MAGI-1b-GFP is absent from

the cell (I).
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infection. Based on the fact that CAREx8 is a transmembrane glycoprotein which will
translocate into the ER for folding, it is possible that MAGI-1 mediates the loss of
CAREx8 by taking advantage of the ERAD (ER-associated degradation) pathway.
Mounting evidence suggests four major ERAD steps: Recognition of defective
proteins (substrates), retrotranslocation from the ER to the cytoplasm,
polyubiquitylation, and proteasomal degradation (21). Furthermore, ERAD has been
separated into three pathways dependent on the lesion site within the defective
protein. 1) It has been well established that co-translational glycosylation is a key
component of the luminal ERAD pathway (ERAD-L) (3). As the growing nascent
chain of a protein, such as CAREx8, is translocated into the lumen of the ER, a 14oligosaccharide core is added to consensus asparagine residues (CAREx8 contains two
sites). Three terminal glucose residues are immediately cleaved by glucosidases I and
II and if the protein is not yet properly folded, the core is reglucosylated. ER-resident
protein chaperones calnexin and calreticulin assist in early folding. Subsequent
activity by ER-mannosidase I cleaves the exposed mannose residues. Progressive deglycosylation leads to recognition by ERAD components, such as OS-9 and XT3-B,
which interact with E3-ligases resulting in ubiquitylation through the Hrd1/Derlin-1
E3 ubiquitin ligase complex, interaction with the p97 complex, which initiate the
retrotranslocation and proteasomal degradation (Fig 1.4.) (20). 2) Lesions in the
transmembrane domain lead to ERAD-M. Little is known about ERAD-M although it
also involves the Hrd1 and p97 complexes. 3) Lesions in the cytosolic domain can
lead to ERAD-C. Several cytosolic E3 ligases, such as RFP2 and CHIP, are known to
ubiquitylate ERAD-C substrates leading to dislocation from the ER via the p97
complex (3).
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Fig. 1.4 Model of the ERAD pathway. Based on the localization of the
lesion, ERAD has three different checkpoints, ERAD-L (lumenial
lesion), ERAD-M (membrane lesion) and ERAD-C (cytoplasmic
lesion).
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1.4. Objective

A major gap in knowledge is how AdVs initially invade the epithelial barrier
and infect the body. The epithelial barrier segregates the microbe infested external
environment from the body’s internal environment, and each epithelial cell has two
distinct domains: an apical or mucosal surface exposed to the air, and a basolateral
surface in close communication with the internal environment. The major CAR
isoform is composed of seven exons (CAREx7) and resides in the basolateral junction
adhesion complex of polarized epithelia where it plays a role in the maintenance of
epithelial adhesion (12). Our group has recently discovered that the eight-exon CAR
isoform (CAREx8) can localize to the apical membrane of well-differentiated polarized
primary human airway epithelia (HAE) where it can mediate apical AdV
infection(14). The discovery of an apical viral receptor results in a paradigm shift
from the commonly held belief that there must be a transient or sustained break in the
tight junction barrier for CVB and AdV to gain access to the primary receptor. This
novel finding also provides the opportunity to directly alter susceptibility to viral
infection by either increasing or decreasing CAREx8 expression. Results from this
study can provide a better understanding of the mechanisms involved in CAREx8
degradation and apical localization. This knowledge can be used to modulate apical
CAREx8 expression in airway epithelia to either reduce the levels of CAREx8 to inhibit
viral infection during adenovirus outbreaks or increase CAREx8 expression levels to
increase adenovirus-mediated gene delivery for gene therapy. In addition, this study
will also allow a deeper understanding of the cellular junction complex interaction
network by demonstrating the interaction between two important components of cellcell junction, CAREx7 and MAGI-1. These results can also provide potential targets to
disturb the junctional localization of MAGI-1, which might be important for the
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interaction between several viral oncoproteins and MAGI-1, which may lead to cell
transformation (17).

1.5. Specific aims and hypotheses
I have been focused on four distinct specific aims which all aim to understand
the localization and abundance regulation of CAR (more specifically, CAREx7 and
CAREx8) and how these regulations alter CAR-mediated AdV infection (Fig.1.5).
The first aim was to detect which PDZ domain(s) of MAGI-1 is responsible
for the interaction between CAREx7 and MAGI-1. Previous data in the lab showed that
only the PDZ3 domain of MAGI-1 binds to CAREx7 by Yeast-two-hybrid analysis and
in vitro pull down. I confirmed this interaction by co-immunoprecipitation from cells
and determined the binding affinity by fluorescence resonance energy transfer
(FRET) and binding analysis. I hypothesized that the PDZ3 domain of MAGI-1 is
responsible for the binding with CAREx7 in vivo. I further hypothesized that PDZ3
domain of MAGI-1 interacts with CAREx7 with high affinity. Moreover, I
hypothesized that mutation of the PDZ3 domain of MAGI-1 will prevent MAGI-1
from localizing at cell junctions due to the lack of the interaction with CAREx7.
The second aim was to detect which PDZ domain(s) participate in the
interaction between the less abundant isoform of CAR, CAREx8, and MAGI-1. I
therefore dissected the CAREx8-MAGI-1 interaction using isolated individual MAGI-1
PDZ domains to determine which domain(s) specifically interacts directly with
CAREx8 by coimmunoprecipitation analysis and also demonstrated the binding
affinity by FRET and binding assays. In addition, I hypothesized that the PDZ3
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domain of MAGI-1 is responsible for the MAGI-1-mediated CAREx8 degradation and
also the suppression of AdV infection.
The third aim was to investigate the mechanism behind the MAGI-1 mediated
CAREx8 degradation. One possibility is that immediately after CAREx8 synthesis, the
two proteins bind and the degradation of CAREx8 starts immediately in the ER
through the ER-associated degradation (ERAD) pathway. I hypothesized that MAGI1b directs CAREx8 to the ERAD pathway leading to degradation by the ubiquitinproteasome system (UPS). Using yeast as a model system, studies on ERAD
machinery show that the recognition of ERAD substrates depends on the binding
between lectin chaperones in the ER and the glycan of the glycosylated substrate. I
hypothesized that the recognition of CAREx8 as an ERAD substrate is through the
lectin chaperones that bind to N-glycosylated CAREx8.
The last aim of my research was to investigate the interaction between each of
the two CAR isoforms with cellular proteins that may mediate or modulate the
regulation of CAR or that may be regulated by CAR. I hypothesized that mass
spectrometry analysis of samples immunoprecipitated by CAR specific antibodies
would detect PDZ-domain containing proteins, including MAGI-1b and LNX, that
interact with both isoforms of CAR.
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Fig. 1.5 Model for viral binding to CAR in human airway epithelia and
aims of this thesis.
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Chapter 2. Material and methods

2.1. Materials
Anti-actin and -RmcB (anti-CAR) were from Millipore (Bedford, MA), AntiFLAG was from Sigma-Aldrich (St Louis, MO), mouse anti-GFP was from Clontech
(Mountainview, CA), anti-V5, anti-ZO-1, rabbit anti-GFP, and fluorescently labeled
secondary antibodies were from Invitrogen (Carlsbad, CA), anti-MAGI was from
Novus Biologicals (Littleton, CO), Anti-myc was from Cell Signaling (Danvers,
MA). Horse-radish peroxidase labeled secondary antibodies were from Jackson
ImmunoResearch (West Grove, PA). Rabbit anti-CAR-1605 and anti-CAREx8-5678
have previously been described (14). MDCK, COS-7 and CHO-K1 cells (ATCC,
Rockville, MD) were cultured under standard conditions (MEM (Invitrogen) with 5%
FBS (PAA Lab, Dartmouth, MA) or DMEM (high glucose for COS-7 and low
glucose for CHO-K1) with 10% FBS, and 1% penicillin/streptomycin, 2 mM Lglutamine). Individual MAGI-1b PDZ domains (PDZ1, 2, 3 and 5) were cloned into
pcDNA/V5/GW/D-TOPO (Invitrogen) for the in vitro pull down assays. Plasmids for
myc-tagged full length MAGI-1c and all PDZ domains (PDZ0-5) were generously
provided by Dr. Zhigang Xu (Shandong University, Shandong, China) and Dr. Stefan
Heller (Stanford University School of Medicine, Stanford, CA) (41). For FRET and
binding assays, MAGI-1 PDZ1, PDZ2, and PDZ3 domains and CAR C-terminus were
cloned (In-Fusion, Clontech) into a pGEX-6p vector (GE Healthcare, Piscataway, NJ)
modified to contain a His-tag upstream of the GST-tag (pHH2). Xfect (COS-7 and
CHO cell line) transfection reagent (Clontech), GenJet (MDCK) transfection reagent
(SignaGen Laboratories), and Lipofectamine (Calu-3) transfection reagent
(Invitrogen) were used for plasmid transfection. Adenovirus vectors and AdV-β-
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Galactosidase (AdV-β-Gal) were from the University of Iowa Vector Core, Iowa City,
IA. Inhibitors used in the study are listed in table 2.1. Primers are listed in table 2.2.
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Table 2.1 Inhibitors list

Inhibitor

Vendor

Cat #

MG-132

Fisher Scientific

AP81-5-15A

Kifunensine

Cayman Chemical

10009437

Eeyarestatin

Chembridge

5138427

Tunicamycin

Enzo Life Science

BML-CC104
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Table 2.2 Primer list

Name

Primer sequence

Notes

N115Q

5’- ATT CTG GTG ATG CAT CAA

For Agilent kit

TAC AGG TAA CGA ATT TAC AAC

Dates
generated
18-Sep2012

TGT CAG -3’
N210Q

5’ - CAT CTG TTA TAT CTG TAA

For Agilent kit

AAC AGG CCT CTT CTG AGT ACT

18-Sep2012

CTG GG -3’
N210Q-2F

N210Q-2R

!

5’- CTG TAA AAC AGG CCT CTT

For PCR-based

17-Dec-

CTG AGT ACT C -3’

mutagenesis

2012

5’- CAG AAG AGG CCT GTT TTA

For PCR-based

17-Dec-

CAG ATA TAA CAG ATG -3’

mutagenesis

2012
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2.2 Methods
Cell culture maintenance

Cell culture techniques were performed under a laminar flow hood using
aseptic techniques. Cell cultures were stored and grown in 25- or 75-cm2 tissue
culture flasks within a humidified incubator at 37ºC and 5% CO2. Used media-serum
mix was discarded and new media-serum mix was added, based upon a pH change
from 7.1 to about 6.0, as indicated by a color change of the media from pink to
yellow. As cells began to divide and reached about 80% confluency, as observed
under 400X total magnification with an inverted microscope, the cell cultures were
divided into new flasks using a ratio of between 1:5 and 1:20 cells to media after
removing attached cells with 0.25% Trypsin-EDTA (Mediatech, Inc., Manassas, VA).
All flasks were supplied with new media-serum mix to a final volume of 5 ml in a 25cm2 tissue culture flask and 10 ml in a 75-cm2 tissue culture flask. Cell viability was
verified before each experimental set using the trypan blue exclusion test (60). Dead
cells appeared blue since the membranes became permeable to trypan blue dye. Cell
viability above 80% was considered good for experiments.

Determination of cell concentration (hemocytometry)
The technique reported was used during cell seeding before transfection and
adenovirus infection. Adherent monolayers of cells were trypsinized from 1-2 flasks
and combined in a 50 ml centrifuge tube. The tube was centrifuged at 150 rcf for 5
min. at 4ºC. The supernatant was aspirated and the cells resuspended in 1 ml culture
medium and mixed gently by pipetting up and down. A clean coverslip was centered
on a hemocytometer between the outside railings over the two counting grids. A drop
of well-mixed cell suspension was placed at each notch. The drop was added once to
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ensure even distribution of cells. Cells were counted with a push button counter using
400X total magnification. Cells were counted in the four corner squares (1mm X
1mm) of the cytometer. These squares were 1/400 mm2. The average value of the
total cells counted in the 4 squares was multiplied by 104 to determine the number of
cells per milliliter. The volume of the mixture was adjusted by dilution with culture
media to an appropriate concentration, depending on the particular assay.

Analysis of PCR products
PCR products were analyzed for DNA presence by running 20 µLof the
sample on 1% agarose gels made in TBE buffer. The molecular weight marker
(MWM) used were 1 kb and 2 log DNA (New England BioLab Inc. Ipswich, MA)
according to the relative sizes of CAR and MAGI-1. The electrophoresis was run for
30 min at 110 V. DNA sizes in the PCR products were estimated by comparing the
position of bands of interest to the closest band on the MWM.

Immunocytochemistry
Cells were kept on ice for 5 min, washed 3 times with ice cold PBS
supplemented with Mg2+ and Ca2+ (PBS +/+). The cells were then fixed with
methanol containing 1% paraformaldehyde for 20 min at -20°C. Cells were rinsed
with ice cold PBS, allowed to come to room temperature, and blocked with 2%
bovine serum albumin in SuperBlock (Pierce, Rockford, IL) for 45 min. Appropriate
primary antibodies were added to cells for 2.5 hrs at 37°C or overnight at 4°C. Cells
were rinsed 5 times with PBS with the last rinse greater than 10 min. Cells were
blocked with 2% BSA in Superblock for 5 min and then incubated with appropriate
Alexa-labeled secondary antibodies (Invitrogen) for 2 hrs at 37°C. The cells were
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rinsed 5 times with PBS and mounted onto glass slides using Vectashield mounting
media with DAPI (Vector Laboratories Inc., Burlingame, CA). Staining was
evaluated by laser scanning confocal microscopy (Olympus FV1000) with a 60X oil
immersion lens; images are shown as either single X-Y or X-Z sections.

Immunoprecipitation and Western blot
Cell cultures were placed on ice for 5 min, washed with ice-cold PBS, and
lysed in buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, protease
inhibitors (20 µg/ml, leupeptin, aprotinin, 10 µg/ml pepstatin, and 17.4 µg/ml
phenylmethylsulfonyl fluoride)) by rocking at 4°C for 10 min. Cells were scraped into
a tube, sonicated five times with 5 pulses using Sonic Dismembrator (Fisher
Scientific, model 100) and centrifuged at 14,000g for 10 min at 4°C. The supernatant
was transferred to fresh tubes and subjected to protein estimation by Bio-Rad protein
assay according to manufacturer’s instructions. Aliquots of each lysate were saved for
Western blot analysis of total protein in immunoprecipitation (IP) or coimmunoprecipitation (co-IP) experiments. For IP or co-IP, an appropriate amount of
primary antibody was added to approximately equal amounts of protein in centrifuge
tubes and rotated at 4°C for 2 hours to overnight. Protein G Sepharose bead slurry
(GE Healthcare) was prepared by washing 3 times with 2X volume of lysis buffer and
once with lysis buffer minus Triton X-100, followed by resuspension in fresh lysis
buffer (50% beads + 50% buffer). 50 µL washed beads was added to each sample
tube with additional rotation at 4°C for at least 60 min. Samples were washed 3 times
with lysis buffer and once with lysis buffer minus Triton X-100 by centrifugation at
17000 rcf, 4°C for 1 min to pellet beads in between each wash. Each IP sample was
resuspended in 100 µL 2X denaturing buffer with dye (for WB) and incubated in a
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heat block at 60°C with shaking at 300 rpm for 5-7 min. Samples were then
immediately vortexed vigorously before spinning at 17000 rcf, 30-60 sec. Only
supernatant was subjected to SDS polyacrylamide gel electrophoresis (10% unless
otherwise indicated). Proteins were transferred to a polyvinylidene difluoride
membrane (Millipore, Bedford, MA), blocked with 5% BSA in PBS, washed, probed
with appropriate antibody diluted in 2% BSA in tris-buffered saline tween-20 (TBST) with sodium azide, followed by HRP-conjugated secondary antibodies (Jackson
Immuno Research, West Grove, PA) diluted in TBS-T (1:10,000). Protein bands were
detected by adding ECL reagents (Pierce, Rockford, IL) for 1 min and imaged on a
Fuji LAS 4000 and/or developed in an X-ray Medical film processor model Konica
SRX 101.

Adenovirus infection
Adenovirus serotype 5 containing the β-galactosidase gene (Ad-β-Gal) or
CAREx7/CAREx8 (University of Iowa Vector Core, Iowa City, IA) was diluted with
OptiMem culture media (Gibco, Invitrogen) without serum to the multiplicity of
infection (MOI) of 100. Growth media was aspirated from cells that had been seeded
for 24 to 48 hours, depending on the experiment, and the cells were rinsed with
phosphate buffered saline (PBS+/+). 250 uL of diluted adenovirus was added to each
well in a 24 well plate (3 ml in 10 cm2 dish) at a MOI of approximately 100 plaque
forming units/cell (PFU/cell), unless otherwise indicated, and incubated for 1 hr at
37°C and 5% CO2 with gentle swirling every 15 min. The inoculum was then
removed, cells were rinsed with OptiMem, and fresh media was added. Cells were
incubated at 37°C, 5% CO2 until further analysis.
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Beta-galactosidase assay

The Galacto-Light Plus System (Applied Biosystems, USA) was used to
analyze adenovirus-mediated beta-galactosidase activity according to manufacturer
directions. Briefly, cells were lysed 24 hours after adenovirus infection. 50 µL of lysis
buffer were added to each well in a 24-well plate for 20 min at room temperature.
Cells were scraped and 2 µL of lysate was added into a 96-well plate followed by 100
µL of a 100X dilution of Galacton and 60 min incubation at room temperature. 200
µL of accelerator was then added just before measuring β-galactosidase luminescence
in Luminometer. Protein concentration was determined by adding 6 µL of lysate into
a cuvette, followed by the addition of 1 ml Bio-Rad reagent diluted (1:10 with double
distilled water (ddH2O)). The mixture was incubated at room temperature for 10 min
and the optical density determined with a spectrophometer set to 595 nm as compared
to a set of standard. Each experiment was performed in 5-6 replicates and lysis buffer
was used as control. Data was analyzed by the two-tailed Student’s T-test (Prism,
GraphPad).

Plasmid transfection
Cells were transfected with plasmids 24 hours after seeding, when cultures
reached over 60% confluence. Xfect (COS-7 and CHO cell line) transfection reagent
(Clontech), GenJet (MDCK) transfection reagent (SignaGen Laboratories), and
Lipofectamine (Calu-3) transfection reagent (Invitrogen) were used for plasmid
transfection according to the manufacturer’s protocol. Transfected cells were used for
immunoprecipitation, Western blot, immunofluorescence, or infected with adenovirus
after incubation for 48 hours. GFP plasmid was transfected into separate wells, under
the same conditions with the cloned domains to monitor transfection efficiency. All
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experiments included both positive and negative controls, as described in the text, and
were repeated a minimum of three times unless otherwise indicated. COS7 cells were
transfected with the cloned domain plasmids to confirm protein expression by
immunocytochemistry and Western blotting. Subsequently, the plasmids were used
for CAR-MAGI-1 PDZ interaction studies.

Cell surface biotinylation
Cell surface proteins were biotinylated with 3 ml per 100 mm plate of 1 mg/ml
sulfo-NHS-biotin (Cat # 21331 Thermo Scientific, Rockford, IL) for 1 hour at 4°C
after first cooling cells on ice for 10 min and washing with ice cold PBS +/+. After
washing the cells again with PBS +/+, any unreacted biotin was quenched with 100
mM glycine for 20 min at 4°C. Washed cells were then incubated with lysis buffer for
another 20 min at 4°C. Cell lysate was immunoprecipitated with NeutrAvidin ultra
link resin (Cat # 53150 Thermo Scientific) and Western blotting with antibody of
interest.

Testing for expression of proteins in E. coli
Confirmed clones of MAGI-1 PDZ domains and CAR C-terminus (pHH2
plasmids) were transformed into E.coli using the Rosetta strain of competent cells
(EMD chemicals, Gibbstown, NJ). Rosetta competent cells are BL21 derivatives that
supply tRNAs for AGG, AGA, AUA, CUA, CCC, GGA codons on a
chloramphenicol-resistant plasmid and are therefore capable of expressing eukaryotic
proteins that contain codons rarely used by E. coli. Transformation was done by
adding 50 ng pHH2 plasmids into 25 µL competent cells in a 2.0 ml centrifuge tube
and kept on ice for 30 min. The tube was heat shocked for 45 sec at 42°C and again
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kept on ice for 2 min. 250 µL SOC medium was added to the cells and the tube
incubated for 1 hr at 37°C with shaking at 200 rpm. Each vial of transformed cells
was then spread on two ampicillin (100 µg/ml) and chloramphenicol (10 µg/ml)
containing LB agar plates (20% and 80%) and incubated overnight at 37°C. The next
day, 3 - 9 colonies of each plasmid were grown overnight as 1 colony per 3 ml of LB
broth containing ampicillin (50 µg/ml) and chloramphenicol (10 µg/ml). Next day,
300 µL of each overnight culture was subcultured into three 3 ml of LB (Amp+,
Chl+) broth (a total of 9ml culture/colony) and grown until an OD600 od 0.6-0.8 was
ontained, after which 1 ml of culture was transferred from each sample into another
tube and stored at -20°C as the zero hour non-induced sample. 10 µL of 100 mM
IPTG was added to each remaining 2 ml culture to induce protein expression and
continued incubation at 37°C. 1 ml samples were taken every hour for a total of 6 hrs.
All samples were centrifuged at 9,500 rpm, 4°C for 5 min. Each pellet was
resuspended in 100 µL PBS and sonicated with 5 pulses to completely lyse the cells.
The lysate was again centrifuged after which the supernantant was transferred into
fresh tubes on ice and the protein concentration determined. Protein samples were
mixed with 2X SDS denaturing buffer and incubated at 75°C for 5 min with shaking
at 300 rpm. 15 µg of protein from each sample was subjected to SDS-PAGE and the
gels were stained with Coomassie blue to look for a protein band of appropriate size.
The sample with the highest amount of protein after induction was chosen and this
clone was used to make and purify the protein of interest. Desired clones were grown
in LB broth and stored at -80°C in cryogenic tubes containing 50% glycerol (1:1 50%
glycerol : cell culture ratio) to make the glycerol stock.

Coomassie blue staining
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Gel containing 10% acrylamide was immersed in 0.2% stain solution (1 g
brilliant blue R250, 100 ml ethanol, 2.5 ml methanol, 397.5 ml ddH2O) for 60 min
and then rinsed briefly with ddH2O. To destain, the gel was placed in 100 ml of 30%
methanol with gentle agitation and changed to fresh destain solution every half hour
until the gel was clean enough to see protein bands clearly. The gel was transferred
into 0.5% acetic acid and subsequently soaked in 4% glycerol for 2 hr. The gel was
dried at 70°C for 50 min in a gel dryer vacuum system (BioRad, model 583) and
scanned for image.

Purification of proteins from BL21 bacteria
On the evening of the first day of purification, Rosetta E. coli containing the
appropriate pHH2 plasmid were taken from a glycerol stock and streaked on a LB
(amp+/chlo+) agar plate and grown at 37°C overnight. The plate was removed the
next morning and kept at room temperature until evening. A 40 ml LB (amp+/chlo+)
broth was inoculated with a single colony from the plate and incubated at 37°C and
200 rpm overnight in a shaker. The overnight culture was subcultured into 1 L of prewarmed LB broth and incubated at 37°C for about 4 hours (until OD600 1.5-1.9). 1
ml of uninduced sample was taken for gel analysis before adding 1 ml of 100 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG) and continued shaking for about 4
hours. 1 ml of induced sample was also taken for gel analysis. The 1 L culture was
then centrifuged in 500 ml bottles at 8,500 rpm, 4°C for 10 min in a Sorvall
centrifuge. The pellet was stored at -80°C with 400 µL of 100 mM PMSF.
Pellets from the 1 L culture were resuspended in 10 ml 2X L&C buffer (Tris-based
elution buffer; 400 µL 1 M Tris, pH 8.0, 0.35 g NaCl, 2 ml glycerol in 10 ml
solution), 10 ml 2X protease inhibitors cocktail (Sigma-Aldrich, St Louis, MO Cat #
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S8830), 40 µL 0.5 M EDTA and 20 µL 1 M DTT. The resuspended cells were
sonicated on ice for 6 min with 30 sec pulses and centrifuged at 9,500 rpm at 4°C for
20 min. The supernatant was filtered through 1.2 micron filters (Whatman, GE
Healthcare REF 10 462 261) to remove any debris. The clarified lysate was pumped
through a Fractogel GST-bind cartridge (EMD) using a BioRad pump at 4°C
according to the manufacturer’s instructions. The Fractogel cartridge bound the GSTtagged proteins while other synthesized proteins pass through the column. Briefly,
after pumping the lysate through the cartridge, the column was washed with 2 ml 1X
L&C buffer, followed by 5 ml ATP wash buffer (2X L&C buffer, 10 mM ATP, 50
mM MgCl2, 1.3 ml ddH2O) and finally, 12 ml 1X L&C buffer containing 1 mM DTT
and 1 mM EDTA. To excise protein without any tag, a GST-tagged PreScission
protease mix (1 ml L&C buffer containing DTT and EDTA and 50-80 µL of protease)
was pumped in the column and allowed to circulate through the system for 5 hours.
Typically the protease was originally at 1.5 mg/ml and desalted. The material in the
recirculated tube was collected as elution 1 (E1). L&C buffer containing DTT and
EDTA was pumped through the column to collect at least 3 more fractions of about 1
ml each and labeled E2, E3 and E4 respectively. The fractions contained tag-free
proteins which were quantified and the quality verified using SDS-PAGE. 3 ml of
reduced glutathione buffer (0.01 g/ml of 1X L&C buffer) without DTT or EDTA was
pumped into the column to remove the GST tags and protease and the column was
subsequently washed with 10 ml L&C buffer without DTT or EDTA to regenerate the
column for future use. The column was stored at 4°C for other purifications while the
purified protein was stored at -80°C. In any situation where GST-tagged protein was
purified, the bound protein was eluted directly with reduced glutathione after washing
thereby skipping the use of protease.
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Protein dialysis
Proteins were purified with a Tris-based buffer that did not allow proper
labeling of the proteins with fluorophores for subsequent experiments. Tris-based
buffer was replaced by dialysis against 3 changes of 2 L dialysis buffer containing 10
mM HEPES (pH 8.0), 0.1 mM EDTA, 0.4 mM DTT, 400 mM KCl and 5% glycerol
at 4°C for minimum of 16 hours (2 hrs; 2 hrs; overnight) using a Slide-a-lyzer dialysis
cassette (Thermo scientific). Each cassette was removed aseptically from its pouch
and immersed in dialysis buffer for 2 min to hydrate the membrane. 2 ml protein
sample was added and the cassette was floated vertically in the dialysis buffer and
stirred gently. A syringe was used to transfer protein samples into and to remove
samples from the cassette after dialysis as directed by the manufacturer.

Protein labeling
Purified MAGI-1 PDZ domain proteins without GST tag were labeled with
FluoroLinkTM Ab Cy3 labeling kit (GE Healthcare Cat # PA33000) while purified
CAR isoforms C-terminus proteins were labeled with FluoroLink Ab Cy5 labeling kit
(GE Healthcare Cat # PA35000) according to the manufacturer’s recommendations.
Protein solution (1 mg/ml) was added to the vial of coupling buffer, mixed gently,
then transferred to the vial of reactive dye and incubated at room temperature with
mixing every 10 minutes. While the labeling reaction was incubating, 13 ml of fresh
elution buffer was added to the column for priming. The antibody-labeling mixture
was carefully added to the top of the column and allowed to enter the resin. 2 ml of
elution buffer was added to the column to separate the mixture into a faster moving
pink (Cy3) or blue (Cy5) band of labeled protein from the unconjugated dye. An
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additional 2.5 ml of elution buffer was then added to the column that will help to elute
the pink/blue band. The labeled protein was collected in a clean tube.

Quantification and calculation of D/P ratio
Cy3/Cy5 bisfunctional dye characteristics Cy3 Cy5
Formula Weight 949.11 975.15
Absorbance max 550nm 649nm
Extinction max 150000M-1cm-1 250000M-1cm-1
Emission max 570nm 670nm
Quantum Yield >0.15* >0.28*
* = for labeled proteins, D/P = 2
An aliquot of the labeled protein was diluted such that the maximum
absorbance was 0.5 to 1.5 AU. The absorbance of each labeled protein was measured
at 280 nm, 552 nm (Cy3), and 650 nm (Cy5) after which protein concentration was
determined with Bio-Rad reagent.

Estimation of Cy3 final Dye/Protein (D/P) Ratios
[Cy3 dye] = (A @ 552nm) / 150000 ( [ ] )= concentration)
[protein] = [A @ 280nm – (0.08 * A @ 552nm)]/ molecular weight of protein
D/P final = [dye]/[protein]

Estimation of Cy5 final Dye/Protein (D/P) Ratios
[Cy5 dye] = (A @ 650nm) / 250000
[protein] = [A @ 280nm – (0.05* A @650)]/ molecular weight of protein
D/P final = [dye]/[protein]
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Cy3/Cy5 Spectropscopy fluorescence resonance energy transfer (FRET)
FRET from each Cy3-labeled MAGI-1 PDZ domain to each Cy5-labeled CAR
isoform was done as described by Hostetler et al.(23, 29) , with an ISS PC1 photon
counting spectrofluorometer (ISS instruments, Champaign, IL) using the following
parameters:
Excitation slit width (back) = 1.0 Emission slit width (right) = 0.5
Excitation band width = 8.00 nm Emission band width = 4.00 nm
Excitation = 550 nm Emission scan = 560-700 nm, 1nm increments, 8
iterations.
Cy3-labeled PDZ=30 nM

Cy5-labeled CAR=0-500 nM Temp 25°C

Briefly, a cuvette was washed with ddH2O and absolute ethanol and
subsequently dried with air. A stir bar and 2.0 ml PBS, pH 7.4, were added to the
cuvette and placed in the spectrophotometer for excitation and scanning so as to prime
the equipment. Proteins were added into the cuvette, allowed to stir for 3 min to reach
equilibrium. The Cy3 labeled protein was excited at 550nm. The emission from
560nm to 700nm was scanned. The cuvette was washed after each round of titrations
before repeating the whole process. The following rounds of titrations were run in
2mls of PBS buffer: 30nM Cy3-labeled protein, plus increasing concentrations of
Cy5-labeled protein (0, 1, 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 500
nM); Cy3-labeled protein with PBS buffer; PBS buffer plus only with increasing
concentrations of Cy5-labeled protein (no Cy3-labeled protein; Cy5 control).
Experiments were done in 5 replicates. FRET data were collected by smoothing
curves and correcting for the controls. Maximum emission peaks at 570 nm (Cy3) and
670 nm (Cy5) were recorded. The change in fluorescence intensity (Fo-F) was
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calculated for each replicate at 570 nm / 670 nm. A plot of the change in fluorescence
intensity with respect to increasing Cy5-labeled protein concentrations was made both
for 570 nm and for 670 nm. Statistical software Sigma Plot – Statistics – Regression
Wizard – Ligand Binding – One Site Saturation was used to calculate dissociation
constant (Kd) values. If needed, the Two Site Saturation function was also tested to
determine the number of binding sites. Linear plot y-axis = 1/(1- Fi/Fmax) and x-axis
= [protein]/Fi/Fmax was also used to determine Kd values.
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Chapter 3. CAREx7 interacts with PDZ 3 domains of MAGI-1.

Rational
We previously demonstrated that CAREx7 and MAGI-1 co-localize at cell
junctions through a PDZ-dependent mechanism in non-polarized cells (15).
Moreover, it appears that CAREx7 can mediate the junctional localization of MAGI-1.
However, MAGI-1 is a cellular scaffold protein that contains six PDZ domains. In
order to understand the molecular basis of this interaction, it is important to
demonstrate which PDZ domain of MAGI-1 is responsible for the interaction between
MAGI-1 and CAREx7. Previous data showed that the PDZ3 domain of MAGI-1
interacts with CAREx7 by Yeast-two-Hybrid and in vitro pull down, however, it was
unclear whether this interaction occurred within cells or how strong this interaction
was. I therefore confirmed the interaction by co-immunoprecipitation from cells and
detected the binding affinity by fluorescence resonance energy transfer (FRET) and
binding analysis. I hypothesized that the PDZ3 domain of MAGI-1 is responsible for
the binding with CAREx7 in vivo. I further hypothesized that PDZ3 domain of MAGI1 interacts with CAREx7 with high affinity. Moreover, I hypothesized that mutation of
PDZ3 domain of MAGI-1 will prevent MAGI-1 from localizing at cell junctions due
to the lack of the interaction with CAREx7.

Results
CAREx7 interacts with the MAGI-1 PDZ3 domain
Co-immunoprecipitation (IP) from cell lysates was investigated in order to
demonstrate that the CAREx7-MAGI-1 PDZ3 interaction can occur in the cellular
environment. FLAG-tagged CAREx7 plasmid was co-transfected with each individual
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Fig. 3.1 CAREx7 interacts with MAGI-1 PDZ3. COS-7 cells were cotransfected with myc-tagged MAGI-1 PDZ domains and FLAG-tagged
CAR Ex7. CAR Ex7 was immunoprecipitated with mouse α-CAR RmcB
and probed with rabbit α-FLAG (CAR, ~46 kDa) and rabbit α-myc
(MAGI-1 PDZ domains; 20-28kDa). CAR Ex7 immunoprecipitated with
MAGI-1 PDZ3 only. Western blot of total lysates confirmed expression
of all PDZ domains, CAR Ex7, and equal loading (actin). Coimmunoprecipitation from co-transfected COS cells with mouse αFLAG, followed by Western blot with rabbit α-FLAG (CAR Ex7) and
rabbit α-myc (MAGI-1 PDZ domains), confirmed interactions between
CAR Ex7 and PDZ3. Transfection was confirmed by blotting lysates
with rabbit α-1605 (CAR), rabbit α-myc (MAGI-1 PDZ domains), and
rabbit β-actin (to confirm equal loading).
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myc-tagged MAGI-1 PDZ domain into COS-7 cells. CAREx7 was immunoprecipitated
48hr post-transfection with monoclonal anti-CAR-RmcB Ab, followed by WB
analysis with FLAG-tag Ab recognizing CAREx7 and myc-tag Ab recognizing the
PDZ domains. Consistent with the yeast-2-hybrid and in vitro results, CAREx7 only
pulled down the MAGI-1 PDZ3 domain (Fig. 3.1). Expression of CAREx7 and each
MAGI-1 PDZ domain was confirmed by blotting total lysate. To exclude the
possibility that the IP was a result of endogenous CAREx7 that would be picked up by
anti-CAR-RmcB, immunoprecipitaion with FLAG Ab directed against the
overexpressed CAREx7 was also investigated (Fig. 3.1). As expected, CAREx7 coimmunoprecipitated with PDZ3.

CAREx7 has a high affinity interaction with MAGI-1 PDZ3
Fluorescence resonance energy transfer (FRET) was investigated next in order
to quantify the affinity of the interaction between the CAREx7 C-terminus and MAGI1 PDZ3 domain. Cy3/Cy5 spectroscopy FRET was used to establish direct binding
and to calculate the intermolecular distance between purified Cy3-labeled MAGI-1
PDZ1 or PDZ3 and Cy5-labeled CAREx7 C-terminus. Cy3/Cy5 labels form a common
donor/acceptor pair for FRET and FRET only occurs if the labeled proteins are in
very close proximity (less than 100 Å) (22). The occurrence of FRET was observed as
a decrease in Cy3 fluorescence intensity (seen as a decrease at 570 nm), and a
subsequent increase in Cy5 fluorescence intensity (seen as an increase at
approximately 670 nm). The maximum peak values were recorded at 570 nm for Cy3
and 670 nm for Cy5 (data not shown) for each titration and used to create binding
curves (Fig. 3.2). In contrast to the lack of interaction between CAREx7 and PDZ1
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Fig. 3.2 Fluorescence resonance energy transfer (FRET) from donor
Cy3-labeled MAGI-1 PDZ domains to acceptor Cy5-labelled CAREx7
C-termini. Emission spectra, linear plot of binding curve between
30Nm Cy3PDZ and 0-500Nm Cy5-CAREx7 and average change in
maximal fluorescence intensity at 570 nm (F0-F) of Cy3-PDZ domains
and Cy5 CAREx7 C-termini upon excitation of Cy3 at 550nm with
increasing concentration of Cy5 CAREx7 C-termini (0-500nM). A) Cy3PDZ1 and Cy5-CAREx7 (no interaction). B) Cy3-PDZ3 and Cy5CAREx7. All emission spectra were corrected for background signals.
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(Fig. 3.2.A , Kd > 500 nM), the change in fluorescence intensity as a function of PDZ
concentration yielded a saturable hyperbolic ligand binding curve indicating high
affinity binding for PDZ3 and CAREx7 with a binding affinity (Kd value) of 2 ± 0.9
nM (Fig. 3.2.B ). FRET for the reacting combination yielded an intermolecular
distance of 46.7 Å further indicating direct interactions. Linear plots of data
demonstrate a single binding site (shown as a single straight line) for CAREx7 with
PDZ3 (Fig. 3.2. B).
Cy3-labeled PDZ domains were titrated with non-labeled CAREx7 (Fig. 3.3)
while Cy5-labeled CAREx7 was titrated with non-labeled PDZ (data not shown) in
direct binding assays designed to account for conformational changes that could occur
during an interaction and alter FRET-derived binding affinities. Cy3 fluorescence on
the PDZ domains was quenched with increasing concentrations of non-labeled
CAREx7 C-terminus, and yielded a saturable binding curve. Consistent with the FRET
studies, no detectable binding was found between PDZ1 and CAREx7 C-terminus.
MAGI-1 PDZ3 and CAREx7 bind each other with high affinity (Kd=3.2±0.7 nM, Fig.
3.3). Although the affinities detected by the direct binding assay were slightly
different than those determined by FRET, potentially due to the greater sensitivity of
FRET (22), the trends were consistent with high affinity binding. These data confirm
that the C-terminus of CAREx7 is sufficient to interact directly with the PDZ3 domain
of MAGI-1, and vice versa (data not shown), with high affinity.

Isolated PDZ3 domain does not alter the adenovirus receptor activity of CAREx7
MAGI-1 behaves as a scaffolding protein that may bring together several
interacting partners simultaneously. I hypothesized that full length MAGI-1 or the

!

38!

!

!

Fig. 3.3 Fluorescent-ligand binding assays show direct binding between
Cy3-labeled MAGI-1 PDZ3, but not PDZ1, with the CAREx7 Cterminus. Cy3-PDZ domain proteins were titrated with increasing
concentrations of unlabeled CAREx7. Emission was measured at 570nm
upon excitation at 550nm. Emission spectra were corrected for
background signal PDZ alone in buffer (PBS) and CAREx7 alone in
buffer. Change in fluorescence was plotted with respect to CAREx7
concentration. A) Cy3-PDZ1 by CAREx7 C-terminus was determined by
quenching of Cy3 fluorescence. B) Cy3-PDZ3 by CAREx7 C-terminus.
Binding curve values represent the mean ± SE, n = 5.
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isolated MAGI-1 PDZ 3 domain may influence CAREx7-mediated AdV infection,
potentially by stabilizing cell surface CAR, increasing the clustering of endocytic
signals, or limiting C-terminal interactions important for endocytosis. In order to test
this hypothesis, I co-transfected CAREx7 expression plasmid together with equal
amounts of full length MAGI-1, PDZ3 domain, PDZ1 domain or empty plasmid
(pcDNA3.1) into CAR-negative CHO-K1 cells. Two days after transfection, cells
were infected with AdV carrying the β-galactosidase reporter gene. AdV transduction
was measured by the level of β-galactosidase expression 24h post-infection (Fig.3.4).
Interestingly, there was no significant difference in viral transduction between
CAREx7 co-expression with pcDNA3.1 (control), full length MAGI-1 or the MAGI-1
PDZ3 or PDZ1 (control) domains.
In order to confirm the result that co-expressed MAGI-1 with CAREx7 does not
change CAREx7-mediated AdV infection, CHO cells were infected with AdV-β-Gal at
different MOI after co-transfection with CAREx7 and MAGI-1 or pcDNA3.1 as
control. Infection levels at each MOI of these two conditions are similar (Fig. 3.5),
which indicates that MAGI-1 does not play a significant role in viral infection.
Taken together, these data suggest that, although MAGI-1 binds CAREx7 and
presumably behaves as a scaffolding protein, full length MAGI-1 does not
significantly alter CAREx7-mediated AdV infection. Similarly, co-expression of
CAREx7 and PDZ3 also does not alter AdV transduction.

Mutation of the MAGI-1 PDZ3 domain causes a loss of co-localization with
CAREx7 at cell junctions
After confirming that CAREx7 binds to MAGI-1 via its third PDZ domain, I
hypothesized that mutation of the consensus PDZ docking motif on the MAGI-1
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Fig. 3.4 Co-expression of MAGI-1, isolated PDZ1 domain, or PDZ3
domain, with CAREx7 does not alter adenoviral-mediated gene transfer
of the β-galactosidase gene. CHO cells were co-transfected with
CAREx7 and MAGI-1 (black bar), PDZ3 (slash bar), or PDZ1 (dotted
bar), or empty pcDNA3.1 plasmid (white bar), followed by AdV-β-Gal
(MOI 100) transduction and analyzed for β-galactosidase activity.
Representative experiment shown, n=4.
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Fig. 3.5 MAGI-1 does not alter the CAREx7-mediated viral transduction
at different AdV MOI. CHO cells were co-transfected with CAREx7 and
MAGI-1 (solid line) or balanced with empty pcDNA3.1 plasmid (dash
line), followed by infection with AdV-β-Gal (MOI = 0, 1, 100, 500,
1000) and analyzed for β-galactosidase activity. Representative
experiment shown, n=3.
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Fig. 3.6 MAGI-1 PDZ3 domain mutant (MAGI-1 GF1012RE) does not strongly colocalized with CAREx7 at cell-cell junctions. COS-7 cells seeded on collagen coated
chamber slides were co-transfected with CAREx7 together with GFP-tagged MAGI-1
or GFP-tagged MAGI-1-PDZ3 domain mutant (MAGI-1GF1012RE). Two days after
transfection, cells were fixed and stained with rabbit-anti 1605 CAR Ab. In contrast
to the cell-cell junction co-localization of CAR

Ex7

(A, D red) and parental GFP-

MAGI-1 (B, E green) as shown in panel C and F (yellow), PDZ3 domain mutant
MAGI-1 GF1012RE remains diffuse throughout the cell (H, K green) when it coEx7

expression of CAR

(G, J red) and shows less co-localization (I, L). Arrows indicate

the cell-cell junctions. Confocal microscopy (60x oil immersion).

!

43!

!

!

PDZ3 domain should eliminate the interaction between CAREx7 and MAGI-1 and
hence reduce the cell-junction localization of MAGI-1. To test this, we mutated the
PDZ docking motif GFGF on the PDZ3 domain to GFRE (GF1012RE). The same
motif on PDZ1 and PDZ2 were mutated (GF673RE and GF844RE, respectively) in
order to serve as controls. COS-7 cells were seeded on collagen-coated chamber
slides and co-transfected with CAREx7 together with parental MAGI-1 or each of the
three PDZ domain mutants. Cells were fixed for immunocytochemistry analysis 48hr
after transfection. In contrast to the strong cell-junction co-localization between CAR
and parental MAGI-1, no specific accumulation of the MAGI-1 PDZ3 domain
mutant (GF1012RE) was observed at cell-cell junction sites despite a significant
accumulation of CAREx7 (Fig.3.6). Moreover, PDZ motif mutants of PDZ1 and PDZ2
domains (GF673RE and GF844RE) remain co-localized with CAREx7 at the cell
junctions (data not shown). These data suggest that CAREx7 binds to MAGI-1
exclusively via binding to its PDZ3 domain and requires the PDZ docking motif on
PDZ3 domain of MAGI-1.

Conclusion
The interaction between the PDZ3 domain of MAGI-1 and CAREx7 was
confirmed by co-immunoprecipitation. The binding affinity between PDZ3 and
CAREx7 is around 2.0 nM, indicating a high affinity binding. MAGI-1 does not alter
the CAREx7 mediated AdV infection at a variety of MOI. Isolated PDZ3 domain of
MAGI-1 does not alter the CAREx7 mediated AdV infection either. However,
mutation of the PDZ docking motif on the PDZ3 domain of MAGI-1 delocalizes
MAGI-1 from cell junctions upon the elimination of the interaction between CAREx7
and MAGI-1. These data support the hypothesis that CAREx7 is required for the
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junctional localization of MAGI-1 and potentially other proteins that simultaneously
interact with MAGI-1.
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Chapter 4. CAREx8 interacts with the PDZ1 and 3 domains of MAGI-1.

Rational:
MAGI-1 appears to play a critical role in the abundance of CAREx8 and apical
viral infection in polarized cells. Previous work indicated that the interaction requires
a PDZ-based interaction (14). We therefore dissected the CAR-MAGI-1 interaction
using isolated individual MAGI-1 PDZ domains to determine which domain(s)
specifically interacts directly with CAREx8.

CAREx8 interacts with MAGI-1 PDZ1 and PDZ3 domains
Co-immunoprecipitation (IP) was used to confirm the CAREx8-MAGI-1 PDZ
interactions. FLAG-tagged CAREx8 plasmid was co-transfected with each individual
myc-tagged MAGI-1 PDZ domain plasmid in COS-7 cells and incubated for 48 hr.
CAR was immunoprecipitated with monoclonal anti-CAR-RmcB Ab which
recognizes the extracellular domain of CAR, followed by WB analysis with Abs that
recognize CAR (FLAG or 1605p) and PDZ domains (myc). Similar to Yeast-2-hybrid
and in vitro translation results, CAREx8 pulled down PDZ1 and PDZ3 (Fig. 4.1).
Transfection of CAREx8 and PDZ plasmids was confirmed by blotting total lysate
(Fig. 4.1).

CAREx8 has stronger affinity for MAGI-1 PDZ3 than PDZ1
The results above show qualitative interactions between MAGI-1 PDZ1 and
PDZ3 domains and CAREx8. We next asked whether there was a difference in the
affinity between PDZ1 or PDZ3 and CAREx8. Cy3/Cy5 spectroscopy fluorescence
resonance energy transfer (FRET) was used to establish direct binding and to
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Fig. 4.1 CAR

interacts with MAGI-1 PDZ1 and PDZ3. Co-IP of

myc-tagged MAGI-1 PDZ domains with FLAG-tagged CAR

Ex8

by

mouse α-CAR RmcB from co-transfected lysates. Blots were probed
Ex8

with rabbit α-FLAG (CAR

, ~46 kDa) and rabbit α-myc (MAGI-1

PDZ domains; 20-28kDa). WB of total lysates confirmed expression of
all PDZ domains, CAR, and equal loading (actin). N, no transfection.
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calculate the intermolecular distance between purified Cy3-labeled MAGI-1 PDZ1 or
PDZ3 domains and Cy5-labeled CAREx8 C-terminus (Fig. 4.2). Cy3-labeled MAGI-1
PDZ2 domain was used as a control for these experiments. Cy3/Cy5 labels form a
common donor/acceptor pair for FRET, and FRET only occurs if the labeled proteins
are in very close proximity (less than 100 Å). The occurrence of FRET was observed
as a decrease in Cy3 fluorescence intensity (seen as a decrease at 570 nm) and a
subsequent increase in Cy5 fluorescence intensity (seen as an increase at
approximately 670 nm) (Fig. 4.2, Emission Spectra for CAREx8 indicate interactions
with A) PDZ1 and B) PDZ3, but not with C) PDZ2). The maximum peak values were
recorded at 570 nm for Cy3 and 670 nm for Cy5 (data not shown) for each titration
and used to create binding curves. The change in fluorescence intensity as a function
of PDZ concentration yielded saturable hyperbolic ligand binding curves indicating
high affinity binding for PDZ1-CAREx8 and PDZ3-CAREx8 with binding affinities (Kd
values) of 7.0 + 0.7 nM for PDZ1-CAREx8 and 0.4 + 0.2 nM for PDZ3-CAREx8 (Fig.
4.2.A, B). FRET for each reacting combination yielded an intermolecular distance of
54.2 and 56.6 Å, respectively, further indicating direct interactions. Linear plots of
data demonstrate a single binding site (shown as a single straight line) for CAREx8
with both PDZ1 and PDZ3. In contrast, no interaction was observed between CAREx8
and PDZ2 (Fig. 4.2.C, Kd > 500 nM) as expected.
Cy3-labeled PDZ domains were titrated with non-labeled CAR (Fig. 4.3)
while Cy5-labeled CAR was titrated with non-labeled PDZ (data not shown) in direct
binding assays designed to account for conformational changes that could occur
during an interaction and alter FRET-derived binding affinities. Cy3 fluorescence on
the PDZ domains was quenched with increasing concentrations of non-labeled
CAREx8 C-terminus, and yielded saturable binding curves. High affinity binding was
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Fig. 4.2 Fluorescence resonance energy transfer (FRET) from donor Cy3-labeled
MAGI-1 PDZ domains to acceptor Cy5-labelled CAR

Ex8

C-terminus. Emission

spectra, binding curves (average change in maximal fluorescence intensity at 570 nm
(F0-F) of Cy3-PDZ domains and Cy5 CAR

Ex8

C-terminus upon excitation of Cy3 at

550nm with increasing concentration of Cy5 CAR

Ex8

C-terminus (0-500nM)), and
Ex8

double reciprocal linear plot of binding curves. A) Cy3-PDZ1 and Cy5 CAR
Ex8

Cy3-PDZ3 and Cy5-CAR
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Ex8

. C) Cy3-PDZ2 and Cy5-CAR
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(no interaction).

. B)
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Fig. 4.3 Fluorescent ligand binding assays of MAGI-1 PDZ domains
Ex8

and CAR

C-terminus. Change in fluorescence intensity of Cy3-PDZ

domain at 570 nm upon excitation at 550 nm and titration with CAR.
Ex8

A) Cy3-PDZ1 by CAR

Ex8

C-terminus. B) Cy3-PDZ3 by CAR
Ex8

terminus. C) Cy3-PDZ2 by CAR

!

C-terminus (no interaction).

Binding curve values represent the mean ± SE, n = 5.
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evident with PDZ3-CAREx8 > PDZ1-CAREx8 (Kd = 2.6-42 nM, Fig. 4.3.A, B).
Although the affinities detected by the direct binding assay were slightly weaker than
those determined by FRET, potentially due to the greater sensitivity of FRET, the
trends were consistent with high affinity binding, as well as CAREx8 having higher
affinity for PDZ3 than PDZ1. Consistent with the FRET studies, no detectable
binding was found between PDZ2 and CAREx8 C-terminus (Fig. 4.3.C). These data
confirm that the C-terminus of CAR is sufficient to interact directly with the PDZ1
and PDZ3 domains of MAGI-1, and vice versa (data not shown), with high affinity.

MAGI-1 PDZ3 decreases viral infection, while PDZ1 inhibits MAGI-1-mediated
CAREx8 suppression to allow Adenovirus infection
Since CAREx8 interacted with the PDZ3 of MAGI-1 with a higher affinity than
PDZ1, we hypothesized that PDZ3 would be the domain of MAGI-1 that is
responsible for the suppression of CAREx8. The effect of co-expressing CAREx8 with
full length MAGI-1, PDZ1 or PDZ3 domains on adenovirus infection was
investigated in CHO-K1 cells that do not express endogenous CAR. CHO-K1 cells
transfected with equal amounts of CAREx8, MAGI-1, PDZ1, PDZ3, or empty
pcDNA3.1 plasmid (control and balance in all multiple transfection conditions) were
infected with AdV-β-Gal 48 hr post-transfection. As expected, expression of CAREx8
significantly increased adenovirus transduction whilst MAGI-1, PDZ1, or PDZ3 did
not cause any significant change in adenovirus infection as compared to pcDNA3.1
plasmid transfected control cells (Fig. 4.4.A). As previously shown, co-expression of
CAREx8 and MAGI-1 reduced adenovirus infection in comparison to cells transfected
with CAREx8 alone (Fig.4.4.B). Interestingly, PDZ1 co-transfected with CAREx8 did
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Fig. 4.4 MAGI-1 PDZ3 decreases viral infection, while PDZ1 inhibits MAGI-1mediated CAR

Ex8

suppression to allow adenovirus infection. CAR-deficient CHO-K1

cells were A) single, B) double, or C) triple transfected with CAR

Ex8

, MAGI-1 (black

bars), PDZ1 (dotted bars), or PDZ3 (white bars), and balanced with empty pcDNA3.1
plasmid (gray bars), followed by AdV-β-Gal (MOI 100) transduction. CHO-K1 cells
were double transfected with CAR
analyzed for D) total CAR

Ex8

Ex8

and pcDNA3.1, MAGI-1, PDZ3, or PDZ1 and

or E) cell-surface biotinylated CAR

Ex8

. Quantification of

at least three individual experiments is shown in all bar graphs. *p<0.05
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not significantly alter adenovirus infection (dotted bar) in comparison to CAREx8
alone. However, co-expression of PDZ3 with CAREx8 reduced adenovirus infection to
a similar degree as MAGI-1 with CAREx8 suggesting that the PDZ3 domain is the
domain contributing to CAREx8 suppression (white bar, Fig. 4.4.B).
We then asked whether there would be any competition between PDZ1 and
PDZ3 with MAGI-1 to increase or prevent the suppression of CAREx8 in the presence
of MAGI-1, and thereby alter adenovirus infection. CHO-K1 cells were triple
transfected with CAREx8, MAGI-1, and each PDZ domain. As expected, CAREx8
alone increased adenovirus infection and co-transfection of CAREx8 with MAGI-1
reduced adenovirus infection (Fig. 4.4.C). Surprisingly, PDZ1 rescued adenovirus
infection when triple transfected with CAREx8 and MAGI-1 suggesting that PDZ1 can
inhibit or prevent MAGI-1-mediated CAREx8 suppression. Co-expression of PDZ3
with CAREx8 at the same time as full length MAGI-1 significantly reduced infection,
however it was not to the same degree as MAGI-1 alone or PDZ3 alone suggesting
that these proteins are not additive and additional mechanisms may be at work. An
intermediate reduction of adenovirus infection was obtained when CAREx8 was
transfected with both PDZ1 and PDZ3 suggesting that there may be a competition
between these domains (data not shown).
Given these surprising results, and the fact that the amount of CAREx8, and
more specifically CAREx8 at the cell surface, is the major factor in adenovirus
infection, total CAREx8 cellular and surface expression was investigated. CHO-K1
cells were transfected with CAREx8 along with pcDNA (control), MAGI-1, isolated
PDZ1, or PDZ3. Two days later, total cell lysates were subjected to WB to detect
MAGI-1 (GFP Ab), CAREx8 (anti-FLAG Ab), or the PDZ domains (anti-myc Ab)
(Fig. 4.4.D). Blots were also probed for β-actin expression to control for protein
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loading. There was a significant reduction in total CAREx8 after co-transfection with
MAGI-1. In contrast, there was no difference in the level of total CAREx8 when cotransfected with PDZ1 or PDZ3 indicating that PDZ3 does not decrease the cellular
level of CAREx8. The cell surface levels of CAREx8 in CHO cells co-transfected with
CAREx8 and MAGI-1 or isolated PDZ1 or PDZ3 was then investigated by cell surface
biotinylation. Co-transfection of CAREx8 with PDZ1 did not reduce cell surface
CAREx8 relative to CAREx8 alone (Fig. 4.4.E). However, a significant and similar
decrease in surface levels of CAREx8 in the presence of full length MAGI-1 or PDZ3
was observed suggesting that, in contrast to the loss of CAREx8 when co-expressed
with MAGI-1, PDZ3 prevents cell surface localization of CAR.

Conclusion
Taken together, our findings indicate that CAREx8 interacts with MAGI-1
PDZ1 and PDZ3 domains with high affinity. Whereas PDZ3 holds CAREx8 within the
cell, PDZ1 can inhibit MAGI-1-mediated CAREx8 degradation, thereby allowing
adenovirus infection. These data suggest that MAGI-1 is a major negative regulator of
CAREx8 protein expression levels and hence cellular susceptibility to adenovirus
infection. Moreover, these results suggest that therapeutics designed to specifically
inhibit the interaction between CAREx8 and either PDZ1 or PDZ3 may be able to
increase (PDZ1) or decrease (PDZ3) the susceptibility of airway epithelia to
adenovirus infection in vivo.
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Chapter 5. ERAD machinery is involved in MAGI-1 mediated CAREx8
degradation

Rational:
MAGI-1-mediated CAREx8 degradation appears to occur through the binding
event between the last four amino acid PDZ binding motif of the C-terminus of
CAREx8 and the PDZ domain of MAGI-1. The mechanism behind the degradation is
unknown and is in stark contrast to the interaction between MAGI-1 and CAREx7.
Since the PDZ-based interaction requires the last four amino acids of the C-terminus
of CAREx8, which is the last portion of CAREx8 to be synthesized, it is likely that the
interaction can only occur after CAREx8 is fully synthesized. One possibility is that
immediately after CAREx8 synthesis, the two proteins bind and the degradation of
CAREx8 starts right away in the ER through the ER-associated degradation (ERAD)
pathway. ERAD is a protein degradation pathway that detects misfolded or mutated
proteins within the ER membrane or lumen and triggers degradation of these proteins.
After recognition, substrates are normally polyubiquitinated, retrotranslocated from
the ER to the cytoplasm, and degraded by proteasomes (42). I hypothesized that
MAGI-1b directs CAREx8 to the ERAD pathway leading to the degradation by the
ubiquitin-proteasome system (UPS). Using yeast as a model system, studies on ERAD
machinery show that the recognition of ERAD substrates depends on the binding
between lectin chaperones in the ER and the glycan of the glycosylated substrate (Fig
5.1). As the growing nascent chain of a protein is translocated into the lumen of the
ER, a 14-oligosaccharide core (GlcNAc2Man9Glc3) is added to consensus asparagine
(N) residues. Immediate cleavage of the three terminal glucose residues by the
sequential action of
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Fig 5.1. Proposed model of MAGI-1-mediated regulation of CAR
protein expression via the ERAD pathway.
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glucosidases I and II yield a GlcNAc2Man9 structure. If not properly folded, the core
is reglucosylated by UDP-glucose:glycoprotein glucosyltransferase (UGGT).
Monoglucosylated oligosaccharides then bind to the ER-resident protein chaperones
BiP, calnexin, and calreticulin. Subsequent activity by ER-mannosidase I cleaves the
exposed mannose residues. Progressive de-glycosylation leads to recognition by
ERAD components, such as OS-9 and XTP3-B, which interact with E3-ligases
resulting in dislocation through the Hrd1/Derlin-1 complex, ubiquitinylation,
interaction with the p97 complex and proteasomal degradation. As a glycoprotein
with two N-glycosylation sites (N106Q and N201Q), it is possible that CAREx8 can
bind to the lectin chaperones involved in the ERAD pathway. I hypothesized that
the recognition of CAREx8 as an ERAD substrate is through the lectin chaperones
that bind to N-glycosylated CAREx8.

Results:
Proteasome inhibition rescues CAREx8 from MAGI-1-mediated degradation
To evaluate the role of proteasome in the MAGI-1-mediated CAREx8
degradation, COS-7 cells were treated with 10µM proteasome inhibitor, MG-132, for
17hr, 2 days after co-transfection of CAREx8 and MAGI-1. Cells only transfected with
CAREx8 balanced with pcDNA empty plasmid vector served as positive control. Cells
co-transfected with CAREx8 and MAGI-1 served as another control. Equal amounts of
protein from each sample were subjected to SDS-PAGE, followed by WB. The
membrane was immunoblotted with mouse anti-FLAG antibody, which specifically
recognizes the plasmid-expressed CAREx8. With the treatment of MG-132, there are
two bands of CAREx8 with sizes of 40kD and 46kD. It is possible that the 40kD band
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Fig 5.2. MAGI-1-regulated CAR

expression is sensitive to ERAD and

proteosomal inhibitors, and ubiquitin. A) Inhibition of ERAD with
Kifunensine (K, 20 µM), Eeyarestatin I (E, 20 µM), or MG-132 (M, 10 µM)
rescues CAR

Ex8

from MAGI-1-mediated loss, while tunacamycin (T, 10

µg/ml) does not rescue and shows a 40 kDa unglycosylated form of CAR
B) Ubiquitin-proteasome system is involved in MAGI-1 mediated CAR
Ex8

degradation. HA-Ubiquitin increases the loss of FLAG-CAR

Ex8

.

Ex8

protein

expression in both the presence and absence of MAGI-1. Representative blots
shown. Blots in A) and B) were stripped and probed with anti-actin Ab to
ensure equal loading. Representative experiment shown.
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of CAREx8 is the unglycosylated form of CAREx8 and the upper band is the mature
form of CAREx8, which indicate that the proteasome inhibitor inhibits the degradation
of unglycosylated CAREx8. The unglycosylated form may represent CAREx8
synthesized after the addition of MG-132 or alternatively CAREx8 that has been
deglycosylated by enzymes within the ER.

Ubiquitin facilitates CAREx8 degradation in the presence and absence of MAGI-1
In order to test the role of ubiquitin in MAGI-1-mediated CAREx8 degradation,
CHO-K1 cells were co-transfected with plasmids encoding HA-tagged ubiquitin and
CAREx8, either in the presence or the absence of MAGI-1, and balanced by pcDNA.
Expression of CAREx8 in each condition was detected by WB (Fig.5.2). Without
MAGI-1, co-expression with ubiquitin suppresses CAREx8 expression, which
indicates that ubiquitin can facilitate CAREx8 degradation on its own. Interestingly, in
the condition of triple-transfection, expression of MAGI-1, ubiquitin and CAREx8, the
CAREx8 expression level is even lower when compared to the condition of CAREx8 cotransfected with MAGI-1 alone. These data suggest that ubiquitin can facilitate
CAREx8 degradation by itself. However, in terms of the role of ubiquitin in MAGI-1mediated CAREx8 degradation, there are two possibilities. One possibility is that
ubiquitin can facilitate CAREx8 degradation regardless of MAGI-1. The low
expression of CAREx8 in the triple-transfected condition with MAGI-1 and ubiquitin
may be the result of two independent CAREx8-degradation pathways. The other
possibility is that ubiquitin can accelerate MAGI-1 mediated CAREx8 degradation.

Eeyarestatin I, a p97-ATPase inhibitor rescues MAGI-1-mediated CAREx8
degradation
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My data above suggest a role for UPS in CAREx8 degradation. I next asked

whether the ERAD machinery plays a role in CAREx8 degradation by using a p97ATPase inhibitor, Eeyarestatin. Eeyarestatin can inhibit the activity of ER membraneassociated ATPase p97, which is associated with the retrotranslocation of ERAD
substrates out of the ER. The inhibitor of p97-ATPase activity stabilizes ERAD
substrates in the ER by interfering with retrotranslocation and hence proteasome
degradation. One day post-transfection with CAREx8 and MAGI-1 expression
plasmids, cells were treated with 10µM Eeyarestatin for 17hr and then analyzed by
WB. By comparing the CAREx8 expression in each condition, a partial rescue of the
MAGI-1-mediated CAREx8 degradation with Eeyarestatin treatment was detected.
However, this rescue was not highly significant in all repeated experiments.
Interestingly, viral infection was not rescued by this inhibitor. This might due to
Eeyarestain rescue the ERAD substrate at a late point, which contribute to the loss of
apical localization ability of the rescued part of CAREx8.

Kifunensine, an α-1,2-mannosidase inhibitor, rescues the MAGI-1-mediated
CAREx8 degradation and the suppression of viral infection
To further confirm the role of ERAD machinery in MAGI-1-mediated
CAREx8 degradation, cells were treated with α-1,2-mannosidase inhibitor Kifunensine
(10µM) for 17hr, 24hr -post transfection of CAREx8 and MAGI-1. Treatment with
Kifunensine consistently rescued MAGI-1-mediated CAREx8 degradation (Fig.5.2).
Since Kifunensine can inhibit the ER resident α-1,2-mannosidase, which will interfere
the glycosylation trimming of CAREx8, I investigated the viral receptor capability of
rescued CAREx8. MDCK cells treated with Kifunensine were infected with an AdV
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Fig. 5.3 ERAD inhibitors alter AdV infection and cell polarity. A) Inhibition of
ERAD with Kifunensine (67µM) increases AdV-β-Gal transduction in MDCK
cells. Average of three experiments, n=6/ experiment. B-C) Proteasome inhibitor
(10 µM MG-132) treatment leads to the loss of cell-cell junctions between
polarized MDCK cells. MDCK cells were treated with B) DMSO (control) or C)
MG-132 for 16hr and then were stained with mouse anti-ZO-1 Ab.
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carrying the β-galacosidase reporter gene. AdV transduction was analyzed by the βgalacosidase reporter assay. Compared to cells without any treatment, Kifunensine
treatment significantly increased the Ad viral transduction (Fig. 5.3).

Tunicamycin, an N-glycosylation inhibitor, does not rescue MAGI-1-mediated
CAREx8 degradation
Considering CAREx8 is a glycoprotein and glycan trimming is the key event in
ERAD substrate recognition, inhibiting glycosylation should either help CAREx8
escape the ERAD machinery or lead to the accumulation of CAREx8 in the ER. Two
days after transfection with CAREx8 and MAGI-1, cells were treated with
Tunicamycin for 17hr. Cells lysate were subjected to WB analysis. Treatment with
Tunicamycin resulted in a strong lower band around 40kD, which matches the size of
unglycosylated CAREx8. The blots show a faint band at the size of 46kD, which is the
size of mature CAREx8 with two extracellular domain sites glycosylated. However, by
calculating the density of the lower bands, there is no significant rescue of CAREx8
from MAGI-1 mediated CAREx8 degradation with Tunicamycin treatment.

CAREx8 is a glycoprotein with two glycosylation sites
To evaluate the importance of CAREx8 glycosylation, three CAREx8 mutants
were generated by site-directed mutagenesis by converting one or both asparagine (N)
residues to glutamine (Q) (N106Q, N201Q, and N106/201Q) using a multi-site
directed mutagenesis kit (Agilent Technologies) and PCR. PCR products were
transformed into DH5α competent cells. A single colony was picked and cultured for
each mutant. The mutants were confirmed by sequencing the DNA of the plasmids
purified from bacterial minicultures.
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In order to check the expression of these mutant plasmids, CHO cells were
individually transfected with plasmids encoding each of three mutants or parental
CAREx8. Cell lysates were obtained for WB analysis to confirm the size difference of
the glycosylation mutants. As expected, expression of the double N-glycosylation
mutant, N106/201Q, shows a ~40kD band, while expression of the single mutants,
N106Q and N201Q, show bands of about the same size of 43kD, as compared to the
parental CAREx8 band at ~46kD (Fig.5.5).
To determine the ability of the CAREx8 glycosylation mutants to act as AdV
receptors, AdV-β-gal infection followed by the β-gal assay was performed in CHO
cells expressing one of each of the three CAREx8 glycosylation mutants. The two
single mutants (N106Q and N201Q) mediated a similar level of viral transduction as
compared to parental CAREx8. Interestingly, the viral transduction level in cells
expressing the CAREx8 double mutant, N106/201Q, was lower than the level of
parental CAREx8 mediated AdV infection. This may be due to less protein expression,
lower cell surface expression, or as demonstrated for CAREx7, decreased AdV-binding
cooperativity. All of these hypotheses require further tests in future studies (Fig.5.4).

CAREx8 glycosylation mutants are subject to MAGI-1-mediated degradation
In order to test my hypothesis that in the presence of MAGI-1, CAREx8 is
recognized by ER-resident lectin chaperones as a degradation substrate via binding to
the trimmed glycan attached to the N-glycosylation sites of CAREx8. With the Nglycosylation site(s) mutated, the three mutants of CAREx8 should either partially
(single glycosylation mutants N106Q and N201Q) or mostly (double mutant
N106/201Q) escape lectin chaperone binding and hence escape UPS-facilitated
degradation. In order to test this, each of the three mutants and parental CAREx8 were
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Fig. 5.4 CAREx8 N-glycosylation mutants are able to mediate AdV
infection. CHO cells were transfected with CAREx8 or each of the three
glycosylation mutants, followed by AdV-β-Gal (MOI 100)
transduction. Representative experiment shown, n=4.
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Fig. 5.5 CAREx8 mutants are all subject to MAGI-1-mediated
suppression and the suppression can be rescued by MG-132 (10µM).
A) Two CAREx8 N-glycosylation single mutants and B) double mutant
are subject to MAGI-1-mediated loss, which can be partially reversed
by blocking the proteasome (MG-132 treatment). Representative
experiment shown.
!
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co-transfected with MAGI-1 into COS-7 cells. Expression of three mutants of CAREx8
and the parental CAREx8 in the presence of MAGI-1 was detected by WB analysis.
Interestingly, MAGI-1 suppressed the protein expression of CAREx8 and all three
mutants (Fig.5.5).

Conclusion
Three approaches were performed to determine the role of ERAD in MAGI-1mediated degradation. Firstly, a proteasome inhibitor was used to confirm that with
the inhibition of the proteasome, the degradation of CAREx8 was rescued. Secondly,
expression of ubiquitin facilitated CAREx8degradation suggesting the involvement of
the ubiquitin-proteasome degradation system. Thirdly, two ERAD inhibitors,
Kifunensine, an α-1,2-mannosidase inhibitor and Eeyarestatin, an ATPase p97
inhibitor inhibits MAGI-1-mediated CAREx8 degradation. However, inhibition of
glycosylation and mutating the glycosylation sites on CAREx8 do not allow CAREx8 to
escape from the MAGI-1-mediated ERAD. These data suggest that although CAREx8
may be subject to ERAD, it is not through the traditional ER luminal lectin-chaperone
based pathway. Potentially ERAD may be due to factors within the transmembrane
or, most likely, the cytosolic ERAD pathway. Future studies will investigate these
alternative pathways.
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Chapter 6. Interactions with CAR detected by Mass Spectrometry

Rational
The main focus of this part of my study is the interaction between each of the
two CAR isoforms with cellular proteins that may mediate or modulate the regulation
of CAR or that may be regulated by CAR. For example, it remains unclear why the
abundance of CAREx8 is lower than CAREx7, and much remains to be understood
about how MAGI-1 regulates CAREx8 abundance. Moreover, two major questions are
still unsolved. First, why do the two isoforms of CAR have distinct localization in
polarized cells? Second, what are additional proteins involved in the regulation of
isoform specific abundance?
I have focused on the difference of the extreme C-terminus of CAREx8 (last 4
aa of the 13 unique aa; -ITVV) and CAREx7 (last 4 aa of the 26 unique aa; -GSIV), by
detecting the PDZ-based interactions between these two isoforms and MAGI-1.
However, the difference between the unique upstream sequences likely contributes to
the isoform specific binding as well by changing the binding affinity through different
amino acid compositions, modifications, for example phosphorylation, and unique
regulation as well. The identification of protein(s) that bind specifically to CAREx8 or
CAREx7 will provide important information about the protein network and potentially
the specific regulation of each isoform. Detecting novel binding proteins is the first
step to revealing the mechanism of regulation.
In order to detect the novel binding partners of each isoform of CAR, methods
used to investigate protein-protein interaction should be applied to isoform specific
protein binding pools. Mass spectrometry has become a new trend for protein
identification since the genomics revolution. It can be used to measure the molecular
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mass of a polypeptide and determine amino acid sequences, attachment sites,
posttranslational modifications, and other additional structures (11). By fragmenting
the protein, followed by ionization, fragments can be specifically ionized and sent
through the LC/MS. Bioinformatic analysis can then be implemented using data bases
of peptide information. This allows a comprehensive report of proteins coimmunoprecipitating with the target protein.
Immunoprecipitation of a target protein with a specific antibody allows
additional proteins binding directly to the target, or potentially in a complex with the
target, to be pulled down or isolated together. Immunoprecipitated CAR subjected to
SDS-PAGE followed by coommasie blue stain shows several bands suggesting
abundant binding proteins. I hypothesize that mass spectrometry will detect PDZ
domain-containing proteins, including MAGI-1b and LNX, that interact with
CAREx8. In order to test this hypothesis, I took three approaches, including GST pull
down, SNAP pull down, and immunoprecepitation in MDCK cells stably expressing
each CAR isoform, tagged with the FLAG-tag sequence, to prepare protein samples
for Mass Spec analysis.

Results:
Neither rabbit anti-CAREx8-5678 antibody nor mouse anti-FLAG
immunoprecipitates over-expressed CAREx8 in Calu-3 cells
Calu-3 cells, a human airway epithelial cell line, were transfected with FLAGtagged CAREx8. Cell lysate was obtained 48 hr post-transfection and pre-cleared by
incubation with protein-G beads. Pre-cleared cell lysates were then incubated with
individual antibodies overnight, followed by 1 hr protein-G beads incubation. Beads
were washed three times after incubation. Protein loading buffer was added to beads
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to denature the proteins on the beads for SDS-PAGE, coomassie blue stain, and WB
analysis.
In order to test the precipitation efficiency of two different antibodies, rabbit
anti- CAREx8-5678, which specifically recognizes the C-terminus of CAREx8, and
mouse anti-FLAG, which recognizes the N-terminal FLAG tag of CAREx8, cell lysate
obtained from Calu-3 cells transfected with FLAG-tagged CAREx8 was subjected to
immunoprecipitation with each antibody. Proteins precipitated with the antibody and
beads were either detected by coomassie blue stain or WB analysis immunobloted by
either rabbit anti-CAR-1605 antibody or mouse anti-FLAG antibody. Coomassie blue
stains of the gel shows similar pull-down smear bands (Fig. 6.1.A) However, only the
rabbit anti- CAREx8-5678 facilitated precipitation of endogenous CAREx8, since same
bands can be detected only by rabbit anti-1605 but not mouse anti-FLAG (Fig. 6.1.B).
For pull down facilitated by mouse anti-FLAG, only the antibody bands were detected
by WB (Fig. 6.1.C).

GST-pull down detect the protein binding partners of CAREx8 in Calu-3
Since there were no obvious CAR specific bands, I therefore took an
alternative approach to obtain protein samples with the potential proteins binding to
CAR. GST-tagged C-terminus of CAREx7, CAREx8 (GST-CAREx7 and GST-CAREx8 ),
or the GST tag itself (negative control) were incubated with Calu-3 cell lysate
containing equal amounts of protein for 3 hr. Glutathione agarose resin (Gold
Biotechnology, G-250) was added to the protein mix for a 2 hr incubation. Proteins
exclusively attached to the resin were denatured following SDS-PAGE coomassie
stain analysis (Fig. 6.2). Two similar bands around 100 kD exclusively appeared on
the gel, which should contain protein(s) pulled down by the GST-CAREx7 and GST-
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Figure 6.1. Anti-CAREx8-5678 antibody and mouse anti-FLAG do not
immunoprecipitate CAREx8 in Calu-3 cells. A) Calu-3 cell lysate or
immunoprecipitate from control (N) or CAREx8 transfected (8) cells, or
Ab with no cell lysate were subjected to SDS-PAGE and Coomassie
blue staining. Duplicate gels from A) were transferred to PVDF and
blotted for B) CAREx8 (5678) or C) the FLAG-tag on CAREx8.
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Figure 6.2. Coomassie blue staining for proteins in Calu-3 cell lysate
subjected to GST-tagged CAR C-terminus bound to GST resin. The red
square indicates the band cut for MS analysis.
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Table 6.1. Ninety-four identified proteins
No.

Identified proteins

1

Alpha-actinin-4 OS=Homo sapiens GN=ACTN4 PE=1 SV=2

Molecular
weight
105 kDa

2

Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2

103 kDa

3

Myosin-Id OS=Homo sapiens GN=MYO1D PE=1 SV=2

116 kDa

4

LIM domain and actin-binding protein 1 OS=Homo sapiens

85 kDa

GN=LIMA1 PE=1 SV=1
5

Splicing factor, proline- and glutamine-rich OS=Homo sapiens

76 kDa

GN=SFPQ PE=1 SV=2
6

Catenin alpha-1 OS=Homo sapiens GN=CTNNA1 PE=1 SV=1

100 kDa

7

Myosin-Ic OS=Homo sapiens GN=MYO1C PE=1 SV=4

122 kDa

8

Villin-like protein OS=Homo sapiens GN=VILL PE=2 SV=3

96 kDa

9

Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1

92 kDa

10

Catenin delta-1 OS=Homo sapiens GN=CTNND1 PE=1 SV=1

108 kDa

11

Villin-1 OS=Homo sapiens GN=VIL1 PE=1 SV=4

93 kDa

12

Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4

95 kDa

13

Epidermal growth factor receptor kinase substrate 8 OS=Homo

92 kDa

sapiens GN=EPS8 PE=1 SV=1
14

Sodium/potassium-transporting ATPase subunit alpha-1

113 kDa

OS=Homo sapiens GN=ATP1A1 PE=1 SV=1
15

Catenin beta-1 OS=Homo sapiens GN=CTNNB1 PE=1 SV=1

85 kDa

16

Transitional endoplasmic reticulum ATPase OS=Homo sapiens

89 kDa

GN=VCP PE=1 SV=4
17

Coxsackievirus and adenovirus receptor OS=Homo sapiens
GN=CXADR PE=1 SV=1
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18

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1

86 kDa

19

Peripheral plasma membrane protein CASK OS=Homo sapiens

105 kDa

GN=CASK PE=1 SV=3
20

AP-2 complex subunit beta OS=Homo sapiens GN=AP2B1 PE=1

105 kDa

SV=1
21

Tax_Id=9606 Gene_Symbol=KRT13 Isoform 1 of Keratin, type I

50 kDa

cytoskeletal 13
22

Heat shock protein HSP 90-beta OS=Homo sapiens

83 kDa

GN=HSP90AB1 PE=1 SV=4
23

High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic

93 kDa

phosphodiesterase 8A OS=Homo sapiens GN=PDE8A PE=1
SV=2
24

26S proteasome non-ATPase regulatory subunit 2 OS=Homo

100 kDa

sapiens GN=PSMD2 PE=1 SV=3
25

DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2

91 kDa

26

Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3

82 kDa

27

Caprin-1 OS=Homo sapiens GN=CAPRIN1 PE=1 SV=2

78 kDa

28

Tax_Id=9606 Gene_Symbol=KRT8 Keratin, type II cytoskeletal

54 kDa

8
29

Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2

68 kDa

30

Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3

110 kDa

31

Actin filament-associated protein 1 OS=Homo sapiens

81 kDa

GN=AFAP1 PE=1 SV=2
32

Programmed cell death 6-interacting protein OS=Homo sapiens
GN=PDCD6IP PE=1 SV=1
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33

Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1

87 kDa

SV=5
34

C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens

102 kDa

GN=MTHFD1 PE=1 SV=3
35

Coatomer subunit beta OS=Homo sapiens GN=COPB1 PE=1

107 kDa

SV=3
36

Taperin OS=Homo sapiens GN=TPRN PE=2 SV=2

76 kDa

37

Myosin-XIX OS=Homo sapiens GN=MYO19 PE=2 SV=2

109 kDa

38

Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1

97 kDa

SV=2
39

V-type proton ATPase 116 kDa subunit a isoform 1 OS=Homo

96 kDa

sapiens GN=ATP6V0A1 PE=1 SV=3
40

Uncharacterized protein C19orf21 OS=Homo sapiens

75 kDa

GN=C19orf21 PE=1 SV=1
41

AP-2 complex subunit alpha-2 OS=Homo sapiens GN=AP2A2

104 kDa

PE=1 SV=2
42

Nucleolar and coiled-body phosphoprotein 1 OS=Homo sapiens

74 kDa

GN=NOLC1 PE=1 SV=2
43

Sarcoplasmic/endoplasmic reticulum calcium ATPase 2

115 kDa

OS=Homo sapiens GN=ATP2A2 PE=1 SV=1
44

Coatomer subunit beta' OS=Homo sapiens GN=COPB2 PE=1

102 kDa

SV=2

!

45

Plectin OS=Homo sapiens GN=PLEC PE=1 SV=3

532 kDa

46

Polyubiquitin-B OS=Homo sapiens GN=UBB PE=1 SV=1

26 kDa

47

DNA ligase 3 OS=Homo sapiens GN=LIG3 PE=1 SV=2

113 kDa
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48

USP6 N-terminal-like protein OS=Homo sapiens GN=USP6NL

94 kDa

PE=1 SV=3
49

Protein unc-45 homolog A OS=Homo sapiens GN=UNC45A

103 kDa

PE=1 SV=1
50

Tax1-binding protein 1 OS=Homo sapiens GN=TAX1BP1 PE=1

91 kDa

SV=2
51

Heat shock protein HSP 90-alpha OS=Homo sapiens

85 kDa

GN=HSP90AA1 PE=1 SV=5
52

Plakophilin-4 OS=Homo sapiens GN=PKP4 PE=1 SV=2

132 kDa

53

DNA replication licensing factor MCM3 OS=Homo sapiens

91 kDa

GN=MCM3 PE=1 SV=3
54

DNA replication licensing factor MCM6 OS=Homo sapiens

93 kDa

GN=MCM6 PE=1 SV=1
55

Trypsin - Sus scrofa (Pig).

24 kDa

56

AP-1 complex subunit beta-1 OS=Homo sapiens GN=AP1B1

105 kDa

PE=1 SV=2
57

Transferrin receptor protein 1 OS=Homo sapiens GN=TFRC

85 kDa

PE=1 SV=2
58

Serine/threonine-protein kinase SRPK1 OS=Homo sapiens

74 kDa

GN=SRPK1 PE=1 SV=2
59

Staphylococcal nuclease domain-containing protein 1 OS=Homo

102 kDa

sapiens GN=SND1 PE=1 SV=1

!

60

Exportin-1 OS=Homo sapiens GN=XPO1 PE=1 SV=1

123 kDa

61

(Bos taurus) Actin, cytoplasmic 1

42 kDa

62

2-oxoglutarate dehydrogenase, mitochondrial OS=Homo sapiens

116 kDa
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GN=OGDH PE=1 SV=3
63

Puromycin-sensitive aminopeptidase OS=Homo sapiens

103 kDa

GN=NPEPPS PE=1 SV=2
64

Tax_Id=9606 Gene_Symbol=KRT1 Keratin, type II cytoskeletal

66 kDa

1
65

Spectrin beta chain, brain 1 OS=Homo sapiens GN=SPTBN1

275 kDa

PE=1 SV=2
66

Interleukin enhancer-binding factor 3 OS=Homo sapiens

95 kDa

GN=ILF3 PE=1 SV=3
67

Aryl hydrocarbon receptor OS=Homo sapiens GN=AHR PE=1

96 kDa

SV=2
68

Ensconsin OS=Homo sapiens GN=MAP7 PE=1 SV=1

84 kDa

69

Alpha-actinin-3 OS=Homo sapiens GN=ACTN3 PE=1 SV=2

103 kDa

70

Oxysterol-binding protein-related protein 3 OS=Homo sapiens

101 kDa

GN=OSBPL3 PE=1 SV=1
71

Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens

118 kDa

GN=UBA1 PE=1 SV=3
72

tRNA (cytosine-5-)-methyltransferase NSUN2 OS=Homo sapiens 86 kDa
GN=NSUN2 PE=1 SV=2

73

Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB

107 kDa

PE=1 SV=3
74

Mitochondrial inner membrane protein OS=Homo sapiens

84 kDa

GN=IMMT PE=1 SV=1
75

LIM domain only protein 7 OS=Homo sapiens GN=LMO7 PE=1
SV=3
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76

AP-1 complex subunit gamma-1 OS=Homo sapiens GN=AP1G1

91 kDa

PE=1 SV=5
77

AP-2 complex subunit alpha-1 OS=Homo sapiens GN=AP2A1

108 kDa

PE=1 SV=3
78

Coatomer subunit gamma OS=Homo sapiens GN=COPG PE=1

98 kDa

SV=1
79

Major vault protein OS=Homo sapiens GN=MVP PE=1 SV=4

99 kDa

80

Zinc finger CCCH-type antiviral protein 1 OS=Homo sapiens

101 kDa

GN=ZC3HAV1 PE=1 SV=3
81

Hexokinase-1 OS=Homo sapiens GN=HK1 PE=1 SV=3

102 kDa

82

Ubiquitin carboxyl-terminal hydrolase 5 OS=Homo sapiens

96 kDa

GN=USP5 PE=1 SV=2
83

Pleckstrin homology domain-containing family G member 6

89 kDa

OS=Homo sapiens GN=PLEKHG6 PE=1 SV=2
84

Cytospin-B OS=Homo sapiens GN=SPECC1 PE=1 SV=1

119 kDa

85

Ras GTPase-activating-like protein IQGAP3 OS=Homo sapiens

185 kDa

GN=IQGAP3 PE=1 SV=2
86

MICAL-like protein 2 OS=Homo sapiens GN=MICALL2 PE=1

98 kDa

SV=1
87

Dynamin-2 OS=Homo sapiens GN=DNM2 PE=1 SV=2

98 kDa

88

Cell division cycle 5-like protein OS=Homo sapiens GN=CDC5L

92 kDa

PE=1 SV=2
89

Desmoglein-2 OS=Homo sapiens GN=DSG2 PE=1 SV=2

122 kDa

90

Targeting protein for Xklp2 OS=Homo sapiens GN=TPX2 PE=1

86 kDa

SV=2
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91

Tax_Id=9606 Gene_Symbol=KRT14 Keratin, type I cytoskeletal

52 kDa

14
92

Tax_Id=9606 Gene_Symbol=KRT15 Keratin, type I cytoskeletal

49 kDa

15
93

Tax_Id=9606 Gene_Symbol=KRT19 Keratin, type I cytoskeletal

44 kDa

19
94

Lipoamide acyltransferase component of branched-chain alphaketo acid dehydrogenase complex, mitochondrial OS=Homo
sapiens GN=DBT PE=1 SV=3
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CAREx8. The band containing proteins pulled down by GST-CAREx8 (indicated in the
figure by red square) was cut out of the gel and sent for MS analysis (Promage, free
sample). Ninety-four proteins were detected and identified in this band and are listed
in Table 6.1. Interestingly, CAR was detected even though it was a smaller molecular
weight than expect for the cut out band. This could indicate that CAR has a very tight
interaction with one or more proteins in this band that can withstand SDS
denaturation. Due to the large number of proteins, another approach was considered.

Immunopercipitation of CAR in MDCK cells stably expressing CAR
The third approach I used to obtain MS samples took advantage of the
doxycycline-inducible MDCK cells stably expressing CAREx7, CAREx8, or RFP (red
fluorescent protein). I first detected the expression of each protein with different
doxycycline doses. Expression of CAREx7 or CAREx8 was not detectable by WB in the
absence of the doxycycline (Dox) (Fig.6.3). With increasing doses of Dox (10 ng/ml
to 200 ng/ml), there is a corresponding increased expression of CAREx7 or CAREx8
(Fig. 6.3.A, B). The expression level of CAREx8 at the MDCK cell apical surface was
detected by surface biotinylation. Increasing apical expression of CAREx8 was
detected with increasing doxycycline dose (Fig. 6.3.B). Same amount of MDCK cells
stably expression CAREx7, CAREx8, or RFP were seeded and the protein expression
were turned on with 500 ng/ml doxycycline. Two days later, cell lysates were
obtained and subjected to a 1hr pre-clear step. Pre-cleared cell lysates were then
incubated with mouse anti-FLAG antibody for 3 hrs, followed by incubation with
protein G sepharose beads for immunoprecipitation. Beads were washed three times
and the beads, presumably with proteins attached, were sent to The Ohio State
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Figure 6.3. Doxycycline dose response in MDCK cells stably
expressing dox-inducible CAR
increases CAR

Ex8

Ex7

or CAR

Ex8

Ex7

and CAR

protein levels but does not affect actin. B)

Apical-surface selective biotinylation of CAR
experiment shown.
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University Mass-Spectrometry and Proteomics facility for MS analysis. (They eluted
the proteins out of the beads with 0.7M urea in glycine solution. The samples were
later precipitated by TCA and followed with 2 X acetone wash. The cleaned samples
were digested with trypsin for 2hr at 37°C. The digests were run by LC/MSMS on
orbitrap using 3hr gradient. The data were searched against the NCBI database (other
mammal) and also analyzed by scaffold. )
Interactions were analyzed in order to determine isoform specific and common
interactions. Proteins that were present in both CAREx7 and CAREx8 samples, but not
RFP, are listed in Table. 6.2. Proteins that specifically bind to either CAREx7 or
CAREx8 are listed in Table. 6.3. Proteins that were present in the RFP sample, but not
CAREx7 or CAREx8, are listed in Table. 6.4.

Conclusion
Potential binding partners of CAREx7 and CAREx8 were detected by Mass
spectrometry. I chose the strategy of immunoprecipitating CAR from MDCK cells
stably expressing Dox-inducible FLAG-tagged CAR for MS sample preparation for
several reasons. Firstly, there is no transfection which reduces potential toxicity.
Secondly, the FLAG antibody should specifically detect the N-terminal FLAG tag
found only in the two CAR isoforms. The N-terminal FLAG tag also should not
disturb the C-terminus binding to its intercellular protein partners. Twelve out of 132
proteins were identified as potential binding partners for both CAREx7 and CAREx8.
Twelve out of 132 proteins are potentially specific binding partners with CAREx7.
Five out of 132 proteins are potential binding partners for CAREx8. Surprisingly, none
of the proteins identified have been previously described as CAR interacting partners.
Moreover none of the proteins identified were PDZ-domain containing proteins.
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These results suggest that potentially my lysis and washing strategy may have been
too stringent or that PDZ-based interactions may not be as strong as the interactions
with the proteins identified. Future studies will confirm the binding between CAR and
each individual protein.
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Table 6.2 Common proteins detected by MS in both CAREx7 and CAREx8 IP
No.

Identified proteins

1

PREDICTED: coxsackievirus and adenovirus receptor homolog

Molecular
weight
43 kDa

[Canis lupus familiaris]
2

PREDICTED: LIM domain and actin-binding protein 1 [Canis

85 kDa

lupus familiaris]
3

PREDICTED: LIM domain only protein 7 [Canis lupus

157 kDa

familiaris]
4

AltName: Full=Calpactin-1 light chain; AltName: Full=Cellular

11 kDa

ligand of annexin II; AltName: Full=S100 calcium-binding
protein A10; AltName: Full=p10 protein; AltName: Full=p11
5

PREDICTED: gelsolin isoform 5 [Canis lupus familiaris]

81 kDa

6

PREDICTED: splicing factor, proline- and glutamine-rich-like

75 kDa

[Monodelphis domestica]
7

PREDICTED: actin-related protein 2/3 complex subunit 5-like

17 kDa

protein-like [Monodelphis domestica]
8

splicing factor, arginine/serine-rich 1B [Pan troglodytes]

28 kDa

9

heterogeneous nuclear ribonucleoprotein A3 isoform a [Mus

40 kDa

musculus]
10

PREDICTED: uncharacterized protein LOC609457 isoform 2

18 kDa

[Canis lupus familiaris]
11

myosin-10 [Bos taurus]

229 kDa

12

PREDICTED: protein phosphatase 1, regulatory (inhibitor)

115 kDa

subunit 12A isoform 1 [Oryctolagus cuniculus]
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Table 6.3 Unique proteins detected by MS in either CAREx7 or CAREx8 IP
Identified proteins unique to CAREx7

No.
1

tight junction protein ZO-2 [Canis lupus familiaris]

Molecular
weight
132 kDa

2

PREDICTED: periplakin [Canis lupus familiaris]

202 kDa

3

glyceraldehyde-3-phosphate dehydrogenase [Sus scrofa]

28 kDa

4

hypothetical protein PANDA_014705 [Ailuropoda melanoleuca]

192 kDa

5

PREDICTED: retinoic acid-induced protein 3 [Canis lupus familiaris]

40 kDa

6

hypothetical protein PANDA_016613 [Ailuropoda melanoleuca]

176 kDa

7

PREDICTED: plectin-1-like [Ailuropoda melanoleuca]

488 kDa

8

PREDICTED: epiplakin [Canis lupus familiaris]

321 kDa

9

vimentin [Ovis aries]

54 kDa

10

keratin 7 [Mustela putorius furo]

39 kDa

11

heterogeneous nuclear ribonucleoprotein D0 [Bos taurus]

33 kDa

12

alpha-actinin-4 [Bos taurus]

105 kDa

Identified proteins unique to CAREx8

No.
1

PREDICTED: clathrin, light polypeptide A isoform 3 [Oryctolagus

Molecular
weight
24 kDa

cuniculus]
2

PREDICTED: barrier-to-autointegration factor-like [Bos taurus]

14 kDa

3

PREDICTED: uncharacterized protein LOC478881 isoform 1 [Canis lupus

25 kDa

familiaris]
4

PREDICTED: hypothetical protein LOC100030834 [Monodelphis

103 kDa

domestica]
5

PREDICTED: 40S ribosomal protein S15-like [Ornithorhynchus anatinus]
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Chapter 7. Discussion

My study focuses on the protein level regulation of the cellular abundance and
localization of two different isoforms of CAR. My data confirmed that the PDZ3
domain of MAGI-1 binds to CAREx7 with a Kd of 2.0 ± 0.9 nM. This interaction is
required for MAGI-1 junction localization. The other isoform of CAR, CAREx8, binds
to both PDZ1 and PDZ3 domains of MAGI-1 with a Kd of 7.0 ± 0.7 nM and 0.4 ± 0.2
nM, respectively. We have previously shown that MAGI-1b can negatively regulate
the protein expression of CAREx8 in non-polarized cells (14). My data show although
CAREx8 binds to two distinct PDZ domains of MAGI-1, only the isolated PDZ3
domain leads to the down regulation the CAREx8 mediated AdV infection. The PDZ1
domain of MAGI-1 does not play a role in suppression of CAREx8 mediated AdV
infection. Surprisingly, PDZ1 can protect CAREx8 from loss in the presence of full
length MAGI-1. Moreover, I tested the hypothesis that MAGI-1 mediates CAREx8
degradation via the ERAD pathway and my data provide evidence for this possibility.
Finally, I detected numerous potential binding partners of both isoforms of CAR,
which might play roles in the regulation of trafficking and degradation of CAR.
It is of great interest to investigate the binding between MAGI-1 and the two
different isoforms of CAR for several reasons. First, both of these proteins are
important for junction adhesion complex stability. Second, both may have roles in
cancer progression. Third, both play roles in viral infection. Finally, it is intriguing
that binding to MAGI-1 leads to distinct fates for CAREx7 and CAREx8. MAGI-1
contains six PDZ-binding domains (PDZ0-PDZ5), any of which may bind to each
CAR isoform. The interactions between isolated MAGI-1 PDZ domains and CAR
were investigated by co-IP, quantitative binding, and FRET assays. My results show

!

85!

!

!

that both isoforms interact with the PDZ3 domain of MAGI-1 and, in addition,
CAREx8 interacts with PDZ1. Binding assays and FRET experiments confirm strong
affinity and direct binding between MAGI-1 PDZ3 and the C-terminus of both CAR
isoforms while the CAREx8-PDZ1 interaction is of lower affinity. Moreover, analysis
of FRET data confirms close intermolecular proximity (< 60Å) and suggest a single
binding site in each CAR C-terminus. The different Kd values of the biding between
CAR and PDZ domains indicate that potentially there may be protein binding
competition among these interactions. The binding affinity between CAREx8 and
PDZ3 is larger than the affinity between CAREx7 and PDZ3, which is larger than the
affinity between CAREx8 and PDZ1. The highest affinity between CAREx8 and PDZ3
might be able to explain the loss of CAREx8 in the presence of MAGI and CAREx7,
occurring in the HAE cells expressing the endogenous isoforms of CAR and MAGI-1.
MAGI-1 is an important cellular scaffolding protein that has been implicated
in cell survival, apoptosis, polarity, and cancer (19, 27, 34). MAGI-1 can co-localize
with ZO-1, a cell junction marker (26), which indicates that MAGI-1 serves as a cell
junction protein playing a role in maintaining the cell-cell junction. Previous data
show that in the absence of CAREx7, MAGI-1 diffuses in the cytoplasm. However, in
the presence of CAREx7, MAGI-1 largely co-localize with CAREx7 to the cell-cell
junction (15). In this study, I confirmed that the PDZ3 domain of MAGI-1 is
responsible for this CAREx7-MAGI-1 interaction. Since no change has been observed
in the expression level of CAREx7 in the presence and absence of MAGI-1, I did not
expect either MAGI-1 or isolated PDZ3 domain would alter the CAREx7-mediated
AdV infection in non-polarized cell lines. Data show that the CAREx7 can mediate
similar level of AdV infection in the presence and absence of either MAGI-1 or
isolated PDZ3 domain in non-polarized cells. However, due to the role MAGI-1 plays
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in maintaining the cell-cell junction, the presence of MAGI-1 might be able to
consolidate the cell-cell junction in cell lines that can polarize, such as MDCK and
HAE, which can reduce the accessibility of viral receptor in the cell junctions and
therefore suppress the viral infection. This hypothesis needs to be tested in future
studies. In addition, since the CAREx7-MAGI-1 interaction is responsible for the
junction localization of MAGI-1, the disruption of the interaction should be able to
eliminate the CAREx7-mediated MAGI-1 junction localization. In order to disturb the
CAREx7-MAGI-1 interaction, the GFGF motif on PDZ3 domain was mutated into
GFRE, which is insufficient to bind to the -GSIV PDZ binding motif of CAREx7. My
data show that PDZ3 domain mutant of MAGI-1 does not co-localize with CAREx7 at
the junction any more, which confirms that the PDZ3 domain is required for the
CAREx7-MAGI-1 binding in vivo and also that the binding contributes to the junction
localization of MAGI-1. These data can provide potential targets to manipulate the
MAGI-1 junction localization and hence MAGI-1-mediated oncogenesis.
Triple transfection experiments in CAR and MAGI-1 deficient CHO cells
provide significant insight into the mechanism behind the regulation of CAREx8 by
MAGI-1. Interestingly, the reduction in cell surface CAREx8 upon co-expression with
the PDZ3 domain of MAGI-1 was not due to a decrease in total CAREx8 protein
expression, as observed with full length MAGI-1. This suggests that CAREx8
degradation likely involves multiple MAGI-1 domains and potentially other proteins
that interact with MAGI-1. Moreover, this suggests that inhibition by PDZ3 may be
reversible if the levels of PDZ3 were under external or temporal control. Coexpression of PDZ1 with CAREx8 did not alter AdV infection. Surprisingly, however,
co-expression of PDZ1 with full length MAGI-1 and CAREx8 rescued CAREx8 levels
and AdV infection. PDZ1 and CAREx8 have a lower affinity than PDZ3 and CAREx8,
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which cannot explain why PDZ1 (as an isolated domain expressed from a plasmid)
rescues CAREx8 degradation in the presence of MAGI-1. There are at least two
explanations for the PDZ1-domain mediated rescue of CAREx8. First, it is likely that
there are other MAGI-1 binding proteins that are involved in this degradation. PDZ1
can block the binding between MAGI-1 and the other proteins required for the
degradation and hence inhibit the degradation. Second, the binding affinity between
MAGI-1 and CAREx8 might be lower than the binding affinity between isolated PDZ1
domain and CAREx8. In that case, isolated PDZ1 domain can out compete the binding
between CAREx8 and MAGI-1, which can prevent CAREx8 from MAGI-1-mediated
degradation. This possibility can be tested by detecting the binding affinity between
the full length MAGI-1 and CAREx8 in the future. Future investigations will provide
greater insight into the mechanism of regulation and whether mimetic of PDZ1 or
PDZ3 may be useful for manipulating the levels of CAREx8 at the apical surface, and
hence altering AdV infection.
This study also gains insight into the mechanism behind the MAGI-1 mediated
CAREx8 degradation by testing the role of the ERAD pathway in the degradation of
CAREx8. As a pathway that detects misfolded proteins for degradation, ERAD
requires the UPS to facilitate the final step of degradation. I first investigated whether
UPS is required for the MAGI-1-mediated CAREx8 degradation by inhibiting the
proteasome degradation using a proteasome inhibitor and by co-expression of
ubiquitin together with CAREx8 in the presence and absence of MAGI-1. Proteasome
inhibitor MG-132, which inhibits the 20S activity, seems to be able to rescue both
glycosylated and unglycosylated CAREx8. In addition, over expression of ubiquitin
can also mediate the loss of CAREx8 both in the presence and absence of MAGI-1,
which suggest that MAGI-1 is not the only factor in CAREx8 degradation and CAREx8
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degradation likely requires a polyubiquitin tag. However, the covalent binding
between ubiquitin and CAREx8 is difficult to detecte by co-IP even with the
proteasome inhibitor treatment (data not shown). Potentially this may be due to an
extremely fast rate of ubiquitin-mediated degradation or due to other possible
mechanisms of CAREx8 degradation other than direct polyubiquitinylation of CAREx8.
Future studies will either modify the buffer conditions (i.e. add de-ubiquitinylation
inhibitors) or investigate potential ubiquitin E3-ligases that may act on CAREx8.
To further determine whether ERAD plays a role in CAREx8 degradation, two
ERAD inhibitors, Kifunensine, an α-1,2-mannosidase inhibitor and Eeyarestatin, an
ATPase p97 inhibitor were investigated. Both inhibitors rescued the cellular
expression level of CAREx8 in the presence of MAGI-1, as detected by WB analysis.
However, only Kifunensine increased the AdV infection level in polarized MDCK
cells expressing endogenous CAREx8 and MAGI-1. This can potentially be explained
by the steps that inhibitors target. Kifunensine inhibits α-1,2-mannosidase, which
trims the mannose right after proteins have correctly folded and are deglucosed.
Inhibiting this step might be able to stop the binding of ERAD lectin chaperones and
hence permit the translocation of CAREx8 from ER to Golgi. Thus, Kifunensine
rescued CAREx8 might be able to traffic to the apical surface and serve as an apical
receptor. However, Eeyarestatin inhibits the ATPase p97, which is known to be
responsible for initiating the retrotranslocation of the ERAD substrate after a series of
glycan trimming and lectin chaperone interactions. Eeyarestatin rescued CAREx8
might have its glycans trimmed, and this might lead to the inability to traffic to the
apical surface and serve as an apical receptor.
Treatment of polarized cells with MG-132 leads to the disruption of cell-cell
junctions, which likely leads to the exposure of the highly abundant basolateral
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receptor isoform, CAREx7, and hence significantly increases AdV infection (data from
others in the lab). In summary, MAGI-1-mediated CAREx8 degradation decreased in
response to all the ERAD inhibitors. Together, these data suggest that the ERAD
pathway is involved in MAGI-1-mediated CAREx8 suppression.
I next asked how ERAD might recognize CAREx8 as a substrate. As a
transmembrane glycoprotein, CAREx8 is translocated into the ER for protein folding
and N-glycosylation modification. It is possible that CAREx8 degradation is via the
ERAD-L pathway, which detects protein lesions that are present in the portion of the
target protein in the ER lumen. A potential ERAD substrate is passed as its glycans
are trimmed and analyzed by lectin chaprones potentially leading to ubuquitinproteasome degradation. I hypothesized that eliminating the glycosylation of CAREx8
could prevent CAREx8 from being recognized and degradation by the ERAD-L
pathway. However, inhibition of the glycosylation by tunicamycin treatment did not
rescue CAREx8 from MAGI-1-mediated degradation. This might due to the ER-stress
triggered by Tunicamycin treatment. Given this surprisingly nonspecific inhibitor
treatment result, single and double CAREx8 N-glycosylation mutants were made to
detect the role of glycosylation in ERAD substrate recognition. Rather, CAREx8 Nglycosylation mutants are still subject to MAGI-1-mediated degradation, which
suggests that other recognition mechanism might be involved.
Lastly, potential binding partners of the two isoforms of CAR are detected
by Mass spectrometry. Among the total of 132 proteins immunoprecipitated by FLAG
antibody in three individual MDCK cell lines stably expressing FLAG-CAREx7,
FLAG-CAREx8 and RFP (serve as a negative control), there are twelve proteins and
five proteins unique to CAREx7 and CAREx8, respectively and twelve proteins
immunoprecipitated by both CAREx7 and CAREx8. Among the twelve unique proteins
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pulled down by CAREx7, there are two known protein binding partners, ZO-2 and α
actin-4, of CAREx7 (24). These results can serve as positive controls to demonstrate
the success of the immunoprecipitation experiment. Among the five proteins
specifically pulled down by CAREx8, “clathrin light polypeptide A, isoform 3” can be
a potential trafficking chaperone contributes to the apical CAREx8 localization.
Surprisingly, CAREx7 did not pull down MAGI-1, which might due to the limitation
of the pull down experiment, including 1) overexpression human CAREx7 in dog cell
line containing endogenous MAGI-1 might reduce the binding affinity between
CAREx7 and MAGI-1 due to the different species. 2) final concentration of NaCl used
for the IP was 100mM, which is slightly different with the usually used concentration
(150mM) for the CAR IP. This salt concentration might change the protein binding
affinity as well. One of the proteins pulled down by both CAREx7 and CAREx8, LIM
domain only protein 7 (LMO7) is of great interest. LOM7 is PDZ domain containing
protein which can localize to the apical membrane domain of bronchiolar epithelial.
Yeast-two-hybrid study showed that LMO7 can also bind to the adaptor protein of
nectin, afadin through its LIM domain at adhesion junction (36). Future studies will
confirm these potential binds and demonstrate their physiology influence.
In summary, my study demonstrates the high affinity PDZ-based CARMAGI-1 binding and their physiological influence. These findings can contribute to
development of druggable target to altering the susceptibility of the epithelium to
viral infection. Moreover, by studying the mechanisms of MAGI-1-mediated CAREx8
degradation, my data extent the newly develop ERAD pathway and potentially
provided a new ERAD substrate to fulfill this complicated, disease-related pathway.
Finally, potential binding partners of the both isoforms of CAR can provide
information on isoform specific trafficking and cellular regulation, which might
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contribute to the understanding of protein trafficking pathway and other cell signaling
pathways.
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